

Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use (II)

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10 Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30 The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., *Nature Med.* 1, 1024-1028, 1995; Benjamin et al, *Development* 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, *Science* 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., *Cancer Res.* 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., *Nature* 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., *Nature* 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., *Proc. Natl. Acad. Sci. USA* 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., *Cancer Res.* 59, 99-106, 1999; Wedge et al., *Cancer Res.* 60, 970-975, 2000; Wood et al. *Cancer Res.* 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., *Cancer Res.* 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., *Cancer Res.* 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or

- 5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by

- 10 (a) compounds which inhibit receptor tyrosine kinase activity,
 (b) compounds which inhibit ligand binding to receptors,
 (c) compounds which inhibit activation of intracellular signal pathways of the
 20 receptors,
 (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
 (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
 25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
 (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine


kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579. Receptor blocking antibodies have been described by Imclone (α -p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A.94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I

15



20

in which


r has the meaning of 0 to 2,

n has the meaning of 0 to 2;

25


R₃ und R₄ a) each independently from each other have the meaning of lower alkyl,

- b) together form a bridge of general partial formula II,



wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

- c) together form a bridge of partial formula III



wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

A, B, D, E and T independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,
 R₁ and R₂ independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

5 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z and has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
 10
 15 more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one or more N-atoms carry an oxygen atom, or a salt thereof.

20


A preferred salt is the salt of an organic acid, especially a succinate.

These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

25


Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example anthranil acid derivatives of general formula IV

30




in which

- A has the meaning of group $=NR^2$,
 W has the meaning of oxygen, sulfur, two hydrogen atoms
 or the group $=NR^8$,
 Z has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$
 $(CH_2)_q$, branched or unbranched C_{1-6} -Alkyl or is the
 group



or A, Z and R^1 together form the group



m, n and o

has the meaning of 0 – 3,

q

has the meaning of 1 – 6,

R_a, R_b, R_c, R_d, R_e, R_f

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/ or R_a and/ or R_b together with R_c and or R_d or R_c together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

X

has the meaning of group =NR⁹ or =N-,

Y

has the meaning of group -(CH₂)_p,

p

has the meaning of integer 1-4,

R¹

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

R²

has the meaning of hydrogen or C₁₋₆-alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

R³

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,

R⁴, R⁵, R⁶ and R⁷

independently from each other have the meaning of hydrogen, halogen or C₁₋₆-alkoxy, C₁₋₆-alkyl or


C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group



- 5 R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.

10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V






V,

15 in which
R¹





has the meaning of group

20






in which R^5 is chloro, bromo or the group $-OCH_3$,



in which R^7 is $-CH_3$ or chloro,




in which R^8 is $-\text{CH}_3$, fluoro, chloro or $-\text{CF}_3$

in which R^4 is fluoro, chloro, bromo, $-\text{CF}_3$, $-\text{N}=\text{C}$, $-\text{CH}_3$, $-\text{OCF}_3$ or $-\text{CH}_2\text{OH}$

in which R^5 is $-\text{CH}_3$ or chloro

R^2

has the meaning of pyridyl or the group



and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases. Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30

which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical

- compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

- The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg.

The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

Combined functional interference with VEGF/VEGF receptor systems and with

- 5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
- 10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.

- 15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.

- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
- 25 tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of

30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefore the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10 Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected
15 A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm³, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

10

15

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP ^{scFv}	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

20

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of

- 5 approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in an inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducting L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm³, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

10

15

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

mock, con.	=	treatment group 1
mock+VEGF-A	=	treatment group 2
sTIE2-cl13	=	treatment group 3
sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPM1XX00-P

15

<140>

<141>

<160> 59

20

<210> 1

<211> 1835

<212> DNA

<213> Human

25

<400> 1

30

```

ttttacagtt  ttccctttct  toagagttta  ttttgaattt  toatttttgg  ataaccaagc  60
agctcttttaa  gaagaatgca  cagaagagtc  attctggcac  ttttgatag  tacataagat  120
ttctcttttt  ttttttaaat  ttttttaaat  agtcacattc  agctcgcttg  ctcaaacagg  180
attcccacat  tgggtgagca  agatgagccc  ataggattcc  agagttaata  cgtaaccgta  240
tatacaaaaca  gccaaaaaac  cataatgggt  ccacagggat  ggagcaggga  agggcctctc  300
taacgtgtcc  tctagtctat  ctctgctaaa  cagaaccac  gtacacatg  ataactagag  360
agcacactgt  gttgaacaga  ggatgtgac  cccaatggc  acttggcagc  atgcagttaa  420
aagcaaaaaga  gacatccctt  aataactgta  taaaaaccag  gcagtccat  taaaggggtt  480
aagaaaaacca  acaacaacaa  aaagcgaggg  actgtctgtt  gtcactgtca  aaaaggcact  540
tggagttaat  gggaccagga  ttggaggact  cttagctgat  acagatttca  gtacgatttc  600
attaaaagcg  ttgatgttta  agagaggaca  ctacagcggt  cctgaaggga  gacgctgaga  660
tggaccgctg  agaagcggaa  cagatgaaca  caaagggaat  aaatctttac  aaccaaatg  720
catttaagcg  acaacaaaaa  aaggcaaac  ccaaaacgca  acctaaccaa  agcaaaatct  780
aagcaaaatc  agacaacgaa  gcagcgatgc  atagctttcc  tttgagagaa  cgcatacctt  840
gagacgctac  gtccaacct  aagtcttcaa  cgacagcttc  acagttagat  tattgtgata  900
aaaaatgact  aagcgatgca  aaaagtttca  tctgttccca  gaatccgagg  gagaactgag  960
gtgatcgtaa  gagcatagcg  acatcacgtg  cgttttctta  atgtccctgg  tggcggtata  1020
gcgagtcctc  cggaaggaca  tctggacacc  actttcagcc  acctccttgc  agggggcgaca  1080
tcocgcaaa  tcatccttta  ttocgagtaa  taactttaat  tcttttctaa  catttacacg  1140
gcaaacagga  atgcagtaaa  cgtccacgtc  cgtccacg  ctgggctgcc  gtccgttttc  1200
ctccacgaac  gggtagcgcg  ttccatgaga  aaggataatt  ggcaatttta  tattccacag  1260
tcaggtgggt  ctgcgatagc  tcatttaatg  ttaaacgcga  tcaggggcct  ctccctccgt  1320
ttctgcagg  gctttttctt  gtcttctcct  tggcgagctc  gtggcgagat  ctctctgtgt  1380
gggggctggc  gtctggcttc  gaggggcact  ccgagtcgt  tctgtgtc  tctcctcgca  1440
ggctggcgac  ctggccacca  ctctccgac  tcgacccctc  caacaagcat  ccgagggcac  1500
gttctccgg  ggtacagacc  gtgtccac  attcgtaacc  actctgttcc  acgtcatcca  1560
gtgtacacgag  ctgcgtgtg  ccggtgctgt  ctggggctcg  aggcctcttc  tctcgtgtgt  1620
cttgagcgg  cgggtagtgc  tctgtcagag  acaaaagcat  tccctctccc  ttccgggctg  1680
atcttggctc  attcatatct  acgccagagt  ccaaaactgg  atcattact  ccgttctctc  1740
cagctctttg  gagaatcaat  gtatgaatgt  ctacactgac  cgttgagct  gccatccaag  1800
gagacgaacc  acgcccggg  gtgaggaaac  ggccct

```

60

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagacc ctggggccctg tgcctaccag 60
 acactaacaac cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tctgtgtgcc cattagggaag gtgggtgacct cgggagctat ttgctctgtg 180
 agtgacacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
 tggcccggtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300
 10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata accctcgcag 360
 agttattagt catcacagct tgatttccat ttataaaggg agaaagtctt tgttttctct 420
 aatgtccaag ctttgactga aaactccggt tttccagtc actggagctg gtgcgtatga 480
 aagaaaatct ttacgaatta gatgggagag aagggaataa gtacttgaa ttagggccct 540
 cacotcccc tgacatcttc catgagccctc ctgagttagt g

15 <210> 3
 <211> 516
 <212> DNA
 <213> Human

<400> 3

20 tagagatggt gtttgatgac ccccgggatc tggagcagat gaataagag tctctggaag 60
 tcagcccaaga catgtgcatc tacatcacag aggcatactg actgtcgctc aacctgaatg 120
 25 gacactctgg gttgattgtg aaagaaatgg ggtcttccac ctgcagctctc tcagaacacg 180
 ttgttaagct tctggggcag agtactgatt ctcttccaca gactatcatt cggaaaccaa 240
 agacctccac tgatgcacac agcttgagcc tctgatgacat cagactttac cagaaagact 300
 tctctgcgcat tgcaggtctg tctcaggaca ctgctcagag ttacaccttt ggaatgtggc 360
 atgaactgga tgaggaaggg ctctatttga acagtgtctt ggccacagag tgcatcaaca 420
 30 tccaagatgc ttttccagtc aaaagaacca gcaaatcatt ttctctggat ctccactcatg 480
 atgaagtctc agagtgtgtt gtgtaaagtc cgtctg

<210> 4
 <211> 1099
 <212> DNA
 <213> Human

<400> 4

40 cccacaacac agggggccctg aaacaagcca gcctctctc tgtggtcagc ttggccccagt 60
 cctgctcact ggaatcacagc ccattgtagg tggggcatgg tggggatcag gggccctggc 120
 ccacggggagc gtagaagaag accttggtccg tgaagaaggtg cctctgggtcg 180
 ggggtgcgctc ttggcccttgc cgtgcccctca tccccgggtg gaggcagcga cacagcaggt 240
 gcaccaactc cagcagggtta agcaccaggg agatgagtc aaccaccaac atgaagatga 300
 45 tgaagatggt ctctccctggt gggcgagaga caaagcagtc cagcaggtag cggcaggggt 360
 ctctgctgcc cacaacaacg ggtcccatgg tccagccgta caggcgccac ttggccataga 420
 ggaagcctgc ctctagcaca ctcttgacga gcacactggc gatcaggtg ccdattcagt 480
 ctcccggtat ggcgaggcga ccatctctct ccaccagat ctgtggccat tgaactctta 540
 cggccgcccag cgcccgctcc acctgtgggt ccttggccgg cagtgcgccg actccccctc 600
 50 cctcttgccg cagccgctct tctgcccag acaggtataa gacatggccc aggtagacca 660
 ggggtgggtgt gctgacgaag aggaactgca gcacccagta gcgagtggtg gagatgggga 720
 aggcctggctc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
 actgctcgtc accccacaact gactgcgcgg ccaggcccag gatggagat cgggaagatg 840
 agagcaccgt cagccagatc ttacccacca cgttcagagt ctctggacc ttgtccagca 900
 55 actcttccac gaagcccacc tcacccatgt tcacccggct tccgtcgcca aggagacaga 960
 gcaactcagt gtgtcagcat ggcactcttc tctgtccgcc agcaacaacg ctgcagggag 1020
 gtctgccacg ccgcttctac cgctgtcctg ccgggcgggc caggtggagg ttgggaacat 1080
 ggcgggagtg acgcccgcg

60 <210> 5
 <211> 1015
 <212> DNA
 <213> Human

<400> 5

65 gaggataggg agcctggggg caggagtggt ggagacacag cgagactctg tctccaaaaa 60

	aaaaagtgtct	ttttgaaaaa	gttgagggttg	aaatgatggg	aaccaacatt	ctttggattt	120
	agtggggagc	ataatagcaa	acacccocct	gggttcgcaca	tgtaacaggaa	tgggaccagg	180
	tgggggcaca	gcoatgtgact	tcccgcocct	ggaaatgtgtg	gtgcaaaagt	ggggcagggc	240
5	ccagagcccaa	gaggagagggg	tggttcgcag	acaccccgagg	atgtcagactg	cccccgacct	300
	gcctttctggc	ggcaacctccc	gggtgctgtg	ttgagtcaagc	aggcatggggg	tgagagcctg	360
	gtatatgtctg	ggaaacagggt	gcaggggcca	agcgttccctc	cttcagccctt	gacttggggc	420
	atgcaccccc	ttccccccaa	acacaaacaa	gcacttctcc	agtatgggtgc	caggacaggt	480
	gtccctctcag	ttctctgtgtt	atgacctcaa	gtctactctg	ggccctcgag	ccagccctgt	540
10	gttttaacct	ctgcgtctctc	aagaccacac	ctggaagatt	cttcttccct	ttgaaggaga	600
	atcatcattg	ttctctttatc	actttcaaga	cattttgtac	ggcagcgga	agttaaacag	660
	aatgtgcttc	ctccctcggg	gtctcacacg	ctccacagag	aatgccacga	gggccctgca	720
	ctggggcaggc	ttctctgtag	aaccccgagg	gcttcggccc	agaccacagc	gtcttggccc	780
	gagcctagag	cagggagctcc	cgaacttctg	cattcacaga	ccacctccac	aattgttata	840
	accaaagccc	ttctgtttctg	ttatttcact	taaatcaaca	tgctattttg	ttttcactca	900
15	cttctgactt	tagctcgtgtg	ctgagccgtg	tatccatgca	gtcatgttca	cgtgtagatt	960
	acgtttttct	tcttacacat	gaaaaataat	gcataagtgt	tagaagaaaa	aaaaa	

<210> 6

<211> 2313

<212> DNA

<213> Human

<400> 6

25	ccagagcagg	cctgggtggtg	agcagggaag	gtgcaccgga	cgccggggatc	gagcaaatgg	60
	gtcttggccat	ggagacacgga	gggttctaacg	gtcggggcggg	gggcagctctc	cggggctgct	120
	gggtatcacct	ggcctaacttc	ttcctcttctg	ttccctccat	ccaatctctc	ctacatctgg	180
	ggctcgtgtct	cttcatgtgtc	tatggcaacg	tgacagttag	cacagagtcc	aaacctcgagg	240
30	ccacccgagc	ccgagccgag	ggcctataca	gtcagctcct	agggctcagc	gcttccagct	300
	ccaactgtac	caagagagctc	aaacttcacca	cccgcgccaa	ggatgccatc	atgcagagtg	360
	ggctgaatgc	tcgcgcggac	ctggaccgga	tcaatgcagc	ctctccgctc	gtccaggggtg	420
	accgggtcat	ctacacgaag	aatcagaggt	acatggctgc	ctcatctctg	agtgagaagc	480
	aatgcacaga	tcaattcaag	gacatgaaca	agagctgcga	gtctgtgtct	ttcatgtctga	540
	atcagaaggt	gaagacgctg	gaggttgaga	tagccaaggga	gaagaccatt	tgccatcaagg	600
35	ataaggaag	cgtgtctgctg	aacaaaacgc	tggcggaggga	acagcttggtt	gaatcggtga	660
	aaacccggga	gctgcagcac	caagagcgcc	actggccaag	gagcaaatgc	aaaggttga	720
	agccctctgc	ctgcocctgg	acaaggacaa	gtttgagatg	gaacctctga	aactgtgga	780
	ggactccatt	atccacgca	gcctggacaa	ctcgggttac	aaaccttacc	atccctctgg	840
40	ctcgggaattg	gcctccatcc	cgagagcctg	cgaccacatg	cccagcctca	tgagctccaa	900
	ggtaggaggag	ctggcccggga	gcctccgggc	ggatattcgaa	cgcttggccc	ggagagactc	960
	agacctccaa	cgccagaagc	tggaaagccc	cgagggcctg	cgggccagct	agggagggca	1020
	acagaaaggtg	gagaaggagtg	ctcaggcccg	ggaggccagt	ctccaaagctg	aatgctcccg	1080
	cgagacccag	ctagcgtctg	aggagaaggg	gggtgctggg	aggaaacagag	acaaacctggc	1140
45	caaggagctg	gaagagaaga	agaggggagg	ggagcagctc	aggtatggag	ttggcatcag	1200
	aaactcagcc	ctggagacat	gcatacaagc	caagtctgag	ccgatgatgc	caagtctcaag	1260
	gccatcgggc	cctgtcccga	accocccagc	catcgaccca	gttagcctct	agggagtctaa	1320
	gaggaaagtc	ctggagctccc	agaggccccc	tgcaggcatc	cctgtagccc	catccagttg	1380
	ctgaggagagc	tccagcgtct	aggacccaag	gatggcccgga	ctcggcggtt	ttccggaggt	1440
50	cgagggatag	gctcacagcg	cccacacaaa	ccccctccc	ccgcoccccaa	ccacccaggg	1500
	ccacatcagc	acaaactcct	gcattgcaaac	ccctgatacc	ctctcacacc	ccagcccgcg	1560
	ctctcagctg	cctcacccag	agcacaacgg	cgcgagagat	acgtcacgca	agcaacggcg	1620
	ctgagctcac	atatacctgt	ggtagtgagg	tcacgtggcc	atgtagacgt	catattaatg	1680
	tatagcgatg	gcgtctgtca	gatgcagcac	gtgcgacaca	gacatgggga	acttggcatg	1740
	acgttccacc	gagatgcagc	aacagcgtca	cgggccatgt	acgcgtcaca	catattaatg	1800
55	tcacacagac	gcggcgatgg	catcacacag	acggtgatga	tgtcacacac	agacacagtg	1860
	acaaacacaa	ccatgcacaa	gacacctata	gatattggca	caacatcaca	tgacgcgatg	1920
	ccctttccaa	cacactttct	accgaattct	caactagtgt	cacgttcccc	cgacctctgg	1980
	acacggggca	aggtatccac	aggatcccat	ccctcccgcc	acagccctgg	gccccagggc	2040
	ctcccccctc	ccagcttctc	ggcctccccc	ccacttctct	acccccagtg	ctcggaccgc	2100
60	gaggttgaga	caggagaagca	ttcacctcgg	ctccttgagc	gtgagtggtt	ccaggagcccc	2160
	ctcggggccc	tgagccgggg	gtgaggggtc	cctgtgtctg	ggagggggag	caactcctct	2220
	cccccaactc	ccagccctcg	ctgtggcccg	ttgaaatgtt	ggtggacatt	aataaatatt	2280
	agtaaatcct	taaaaaaaaa	aaaaaaaaaa	aaa			

<210> 7

<211> 389

<212> DNA
<213> Human

<400> 7

gccccaaaaga tggccttcaaa agtaagaatg aaacatttga tccattcagc ttttaggctat 60
gccactgggat tcatgtcttag aaaagatagag ataatttctg taaagaaaatg aagaccttgc 120
tattctcaaaa tcagatccctt acagatccag atttcaggaa acaataacat aggggactaa 180
cttttcttgtt tcagattagt ttttctcctt tgcaccagc tatataatat gaggaagtat 240
tgactttttaa aaagtgtttt agttttccat tcttttgata tgaaaagtaa tatttcggga 300
gaacctgag ctattataaa tctatgtgac tagtgcgtat atattggtct gaatttgttc 360
tctttttgtg gtgtccagtg ggtaacatc

<210> 8
<211> 157
<212> DNA
<213> Human

<400> 8

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggtttttagt 60
gaagcaggaa gcaagcccac taaaactgtg aatttggcat gaggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

<210> 9
<211> 561
<212> DNA
<213> Human

<400> 9

aatagtcaaa acataaacaa aagctaatta actggcactg ttgtcacctg agactaagt 60
gatgttggat gctgacatac aggtccagcc agcagagaaa gaattctgaa ttccccttgc 120
tgacttggat tatcttgtaa catatgggtg acaaaactgt gtgtatttct ttttctacct 180
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tctctgattt ttgcctgatt aatctctggt gagctctact tgttgctcatt caagatttta 300
tgatgttgaa aggaaaagtg aatgtgacct ttaaaaaatt tatatttgggt gatgatagtc 360
tcaccactat aaaaactgtca attattgacct aatgttaaaag atatccatca ttgtgatata 420
ttaaccttat aatgtgatct cttaaatggag aattcttaat ggaatggata tcccctgac 480
40 ttttctttaa aatttctctg cacacacagg acttctcatt ttccaaataa tgggtgtact 540
ctgcccacat tcttaggaaa a

<210> 10
<211> 1508
<212> DNA
<213> Human

<400> 10

cacaaaacag agagactcca cggctctgct gagcacggcc agcctcctag gctccagcac 60
tcgcaggctcc atttctctgc acgagcctct ctgtccagat ccatagacac ggtcagctca 120
gggtgcggcga gcagtaacag gacaagtaacc agcagcagct cctctgaaca gagactgcta 180
ggaatcatctc tctctccggg cctctgttgc gatggcataa tccgggtgca acccaaatct 240
55 gagctcaagg cagctgagct taagccactg agcaaggaaag atttggcgct gccagccact 300
agggtgtagg actgtggcaa gtgcataatgt aaggagtgtca cctaccacca gctcttgcca 360
tcagactgaa tctgtgcacaa gcaagtgcctt tgcctcgccc tgcacagatg gtcagccatg 420
actgtgtgat gctgtgtgaa aggtctcttc tatcactggt ctaatgatga tgaggacac 480
tgtgtgtgaca acccatggtc ttgcagccag tctcactggt tctcactggt ttccagccaa ggggttgctt 600
60 ggtgtcatgt cctcttcttt gcttctgtta tgggtttacc ttccagccaa ggggttgctt 600
aaattgtgccc aggggtgtta tgaccgggtt aacaggcctg ttgcccgtg ttccagccaa ggggttgctt 600
aacaacagtt gctgcaaatg tcccactgtc ccccttagga actttgaaaa accaaccatg 720
catcattaat caggaaatatt acagtaatga ggattttttc tttctttttt taataacat 780
atgcaaccaaa ctacaacagtt ataactcttg cactgttaat agaaagtgtg gatagtcttt 840
65 gctgttttgc gtgaaatgct tttgtccat aactgatag aactgatag ctgtgtgaaa 900
ctcagctaat ggagctcaaa gtatgagata cagaacttgg tgaccatgt attgcataag 960
ctaaagcaac acagacactc ctaggcacaag tttttgtttg tgaatgtac ttgcaaaaact 1020

tgtataattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080
 gtatatacaa taatatTTgc aactgtgaaa aacaagTggt gccatactac atggcacaga 1140
 cacaaaaatc tatactaata tgttTgacat tgggaagaat gtgaatcaat cagtattgtt 1200
 ttgatttgta ttttgcctta cagaagacct ttattTgaag actctgattt ccccttTgagc 1260
 ttcattgtata ttgtacagtt acagtataaat tcaaccttta ttttctaatt ttttcaacat 1320
 attgttttagt gtaagaata tttattTgaa gttttattat tttataaaaa agaataTTta 1380
 ttttaagagg catctttacaa attttgcctt ttttatgagg atgtgatagt tctgtcaaat 1440
 gagggggttac agatgcattt gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
 aaaaaaaa

<210> 11
 <211> 389
 <212> DNA
 <213> Human

<400> 11

gggcaggTga tcagggcaca ctttcccggt ccattgagac cggcaccca 60
 tctgtccagc tcttccctatt tttatgatga tgaccatcca cgttgagaca agtgcccgac 120
 aggatgggtg gccagcgtga agcacaggcc gctctgcact cgtgataga acagcccgta 180
 ctgtctctgt ggaaccccaa ggggcagatc ttactgcagt agagctctgt acattttctta 240
 cagcgacaga gtgcacagcc gtgctttatt ttcagcaatc caagtggaca atactttgca 300
 cagattatgg gtctgcactt ctggggcctt gggcggcact cacagatctc acagtttttg 360
 acctcggtcg cgaccacgct ggggtaccga

<210> 12
 <211> 981
 <212> DNA
 <213> Human

<400> 12

tttttttttt ttggattgca aaaattttatt aaaattTggag acactgtttt aatctttcttg 60
 tgccatgaga ctccatcagg cagctctaca agaccactgg agggctgagg atcacttgag 120
 cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
 aagacccttt caagcagtaa gctgcactgt tgcttTgttg ggtcattaaa aaccctagtt 240
 taggataaca acatatttaac caggggcaaaa tacaattTgt tgatgcttgt tagtagagta 300
 acctcagaat caaaattggaa cggtttttaca gtgatattcat tatatttcat ttggcagaat 360
 cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacttagtt 420
 taggataaca ggtctgcctg ttgaaagatg aaaaaataa cccattttaa atttgccta 480
 ctcaattttc ttctcagTca cattttaact tttaaacagc taactcactcc catctacaga 540
 ttaaggttct tatgcccacca aaaccttttg ccacctttaa aatttctctt aaagtTttaa 600
 ctaatgcctg cattttctca atcatgaatt ctgagctcct tgcttcttta aaacttgctc 660
 cacacagTgt agtcaagcgg actctccata cccaagcaag actccacact ttcaaaaactg 720
 taccaggagc agaaccatta agctgggtcca ggcaagtTgg actccacact ttcaactctc 780
 agctttctat ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggTcttc 840
 agtagctatt ctcatctctc ctgggggaca caactgtcca taaggTgcta tccagagcca 900
 cactgcact gcaccagcca ccatacctca caggagtTga ctccaccag cgcctgttat 960
 ataagagttc ttttgatgac g

<210> 13
 <211> 401
 <212> DNA
 <213> Human

<400> 13

ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
 aagagagccc ggccgcagag catgtgactg ctgggaccta tgggataggc aacactgccc 120
 tctctccccc agagcgacccc cccgggcagg tggggcccca aggaatgacc cagcaactgc 180
 tccctaccca gcacactctc ttactgcca cctgcaatta tgctgtgaag atgactgggt 240
 gtggtctaca cgattcagag aaatcaagat catgaccta tttaggcaaa gagagaaact 300
 tggagaattg ctgaggacta ctgaaccttg ttttgccttt ttaaaaaata ctaaatcttc 360
 acctcagcat attttagttg cattaaaatt aagctgatat t

<210> 14

<211> 1002
 <212> DNA
 <213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
 acagttgtgg agaacagggt gagtagagca acaacaacaa aagccttatgc agtcaccttc 120
 10 ttgaaaaatg ttaaatataa gtccattttt cttgtgccag ctgggttttag cttagaggtag 180
 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaaag caagtttaact 240
 gaagtaataa tctggggccc atgcaccccc cactaagtae ttgtgcacca tggttgatct 300
 taaaagtcat ttttctactgt ttgactcaga atttgggact tcagagtgcaa acttcattgc 360
 ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gaggtagttt 420
 15 tggctataac cgaatgttaa atccaccttc aaacaacaaa gtttgacag actgaaatgt 480
 tactgaaaac aatgggtgcca tatgtcccaa agacatttcc ccaagataac tgccaaagag 540
 tttttggagg ggacaatgat catattattat gtaggagcct tgatatctct gcaaaataga 600
 attaatcacg ctcaaatgga gtagtaacca agcttttctg ccaggagaag acaacaacatc 660
 actacgaaca tgagagtaca agaggaactt ttcataatgc attttttcat tcatacattc 720
 attcaataaa cattagccaa gctaattgtc caagccactg tgccaggat taacaatata 780
 20 acaacaataa aagacacagt ccttcctctc aaggtgttca gtctagtagg gaagatgatt 840
 attcattaaa atttttgggt catcagaatc atgaggagct tgtaaaaaat tgtaattcct 900
 gcctatgttc tcagatattc tggtttagtc aggagtgagg acccaaaatc aattcttcta 960
 acaaacacta aaggtgattc taacacaggc ggtgtgagga cc

<210> 15
 <211> 280
 <212> DNA
 <213> Human

30 <400> 15

cgaggtgggc caccogtgtc tgggtctgaga tttttaaatg aggtattacat tatcttattt 60
 ataattctcc tattctaatc tatgtatttc ttacaattaa atgtattcaaa taactcttaa 120
 aacattattt agaaaacaa tgccataatc cttataagac taataaaaat accaagatga 180
 35 aactgtatta tgacttccaa tttttaaaaa tttaaaaaaa tggtagtggt tgtaagcac 240
 caatcttaac tatttccact gcccgggcgg ccgctcgagg

<210> 16
 <211> 2041
 <212> DNA
 <213> Human

40 <400> 16

ccccccgacg aactcccccc tgggaatagga tttttaaaac ccttgacatc tagaaatcct 60
 atagaggtta gcaattttta ggtaaaaaata tgggtgcccc tacagggato atgcacttc 120
 cttaaaaaca attcagcaca tatgtataaa gaacaccttt taaaacctat tgacttgaa 180
 ctacagacac agtgaatgctg aagacactaa acaaaaactg aaaaacctat taacttgata 240
 50 aattttgta ttgctctctt tagagacttt ataactctta gtgtattttc aaggacttga 300
 atttaataat ggggttaatta cacaagagct aaaggatttt ttaaaaaaaa gtattttttt 360
 ttaactctag catcaattct tttataaaga atgctaataa aattacattt ttgtttcagt 420
 aaaaactgaag atagaccatt taaatgcttc taccaaaatt aacgcagctt aattaggagg 480
 caggtacata ttttctctgt aacattttt gtccaagcatg tctaaccata aaagcaaatg 540
 55 gaatttttaa aggtagattt tttttccatg atgcattttt ttaataaatg tgtaaaagaa 600
 tagaaaaaaa gcaactgagtg tgtttctctg aagtataagg gtctaatgaa aataaaaaaa 660
 atagattttg ttatagctgt acattttaac agtcatagta tttagcgttt cgtgaccagt 720
 gcaattttga ctctctcagg atcaaaaata gaggctgcca actgtattaa atctctctcc 780
 accccctcca ccagttggct cacagcttcc tgggtgggtg ttgtcatata atccattggg 840
 60 ccgaatgaaa catagaagcag atgcagcttg gaggggccgg gtctcgagcat tcaactcttg 900
 ttctctgtaa ttatagttat tgtcttttgg tatagcatcc ataatgtctt tctgttagag 960
 tgggtgtcca ctatgtccaga gtccactggt tgggttatta ccaacttaac cttagtact 1020
 atgctgtttt ttatacaaaa gcacataaagc tgtgtctctt ggaacactgc tcgtaatatt 1080
 ctggaactag tgaatatgaag taaatgtcac tctactgtca ttaaaataaa acccaattct 1140
 65 ttgactttgc ctatttttcc aaatcctggt caaaaactgc aactgacata tctctccata 1200
 gtaaatgact ctgggagagt gctaagtcca gagcctcaga ctggttgatc atctgatagt 1260
 aagagtctgt acttgtgata ttctggtcat aagaatagta atgccactt tcagaggata 1320

taccagagtg	aaccacaacg	gaacttaata	gatagggcac	caattttgtg	caggaagctt	1380
cacaggtccc	tgaaggtctt	aatttttttg	caaggttttc	actaagatca	gtgaagctca	1440
catctacaga	ccaactttct	gacaatgaag	agaagaaggt	aattctctta	actggcaact	1500
ccaataaccg	tgcccgatga	tacattgtct	aaaaatttcc	ttctcacatg	atactcttga	1560
tcatatgaaa	atctcaggag	agtaagaata	aggtattcag	gtctctccgt	gatttgcata	1620
gtttttctcg	cattttgcag	agaggcacag	ttttcacaa	aatattgggt	atcacccagt	1680
agaattctcg	gagcccaaaa	aataatttat	taagtccagt	actgaagggt	tggtttccac	1740
tcccggtttc	tgaggtaaat	ctttatttaac	aagaattctg	ttagattcgt	tagggacaga	1800
agtgttttca	gaacagtaaa	actcattagg	aggactgcct	attggtttttt	cattcacaga	1860
tgagtcacag	atgaaggcag	ctgtgtgttg	attataaaact	actggctctt	ctgaaggacc	1920
gggtcacagc	gcttgcatta	gaccaccatc	ttgtatactg	gtgtgatgat	ctgtactctt	1980
gacagacatg	ttttccaag	aaggaggaag	acaaaacgca	agcgaaagat	ctgtaaaggc	2040

15 <210> 17
 <211> 235
 <212> DNA
 <213> Human

20 <400> 17

cgccccgggc	aggtgtcagg	ggttccaaac	cagcctgggg	aaacacagcg	tagacccttc	60
acctctacaa	ataaaaaaatt	aaaaaattag	ccaggtgtgg	cagcgacaac	ctgtagtctc	120
agatactcag	gagactgagc	tggaaggat	cacttgagcc	caagaagttc	aaggttacag	180
tgggccacga	tcattgtcatt	acactccagc	ttgggtgaca	aatgagact	gtcta	

25 <210> 18
 <211> 2732
 <212> DNA
 30 <213> Human

<400> 18

gtgtggagtt	tcagctgcta	ttgactataa	gagctatgga	acagaaaaag	cttctgtggt	60
tcattgtgat	aactacttta	tatggagctt	catggagcct	gttactctta	ttattcttgt	120
aaatatattc	ttcttggtga	tcacattgtg	caaaatgggt	aagcattcaa	acactttgaa	180
accagattct	agcaggttgg	aaaacattaa	gtcttgggtg	cttggcctgt	tcgctctctt	240
gtgtctctct	ggcctccact	ggctccttgg	ttgtcttttt	attaaagagg	agactattgt	300
gatggcatac	ctcttcacta	tatttaattg	tttccaggga	gtgttcattt	tcactcttca	360
ctgtgctctc	caaaagaaag	tacgaaaaga	atatggcaag	tgcttcagac	cattcactgt	420
ctgtggaggc	ctccccactg	agagtcacca	cagttccagt	aaggcatcaa	ccaccagaag	480
cagctgcctg	tattctctgt	gcacacagag	tggtataaga	agaattgtga	atgatactgt	540
gagaaaacaa	tcagaattctt	cttttatctc	aggtgacatc	aatagcactt	caacacttaa	600
tcaagggtgc	ataaatctta	atatattatt	acaggactga	ctaactcgct	cttgagagcc	660
catcttcaag	atttatactc	tttagaggac	attcactgaa	caatgcctgg	gatacaagtg	720
ccatggatgc	tctaccgcta	aatggtaatt	ttacaacagc	acttctcgct	caagaagggtg	780
actataatga	cagctgtgca	gttgtggact	gtggactaag	tctgaatgat	actgcttttg	840
agaaaatgat	catcttcagaa	ttagtgcaca	acaacttacg	gggcagcagc	aagactcaca	900
accctgagct	cagctaccca	gtcaaacctg	tgattggagg	tagcagcagt	gaagatgatg	960
ctattgtggc	agatgcttca	ctctttaatg	acagcgacaa	cccagggtctg	gagcttcctc	1020
acaaagaaat	cgaggccaac	cttattctct	agcggactca	ctccctcttc	caccagcccc	1080
agaagaaagt	gaagtccagg	ggaaactgaca	gctatgtctc	ccaactgaca	gcagagctgt	1140
aaagatcact	acagtccccc	aacagagact	ctctttatgc	aaagcatgcc	aatcttagag	1200
actctcccta	tcoggagagc	agccctgaca	tggaagaaga	ctctctcttc	tcogagagga	1260
gtgagaatga	ggacatttgc	tataaaagca	tgccaaatct	tggaagctgc	catcagcttc	1320
agatgtgcta	ccagatcgac	aggggcaata	gtgatggtta	tataactccc	attacaagaag	1380
aagggtgtat	tcagagaagg	gatgttagag	aaggacaaat	gcagctgtgt	acaagctctt	1440
aatcacaagc	ataaggaatt	ccaagggcca	catgcgagta	ttataaaata	aagacacctat	1500
tgccctgagc	cagctccctc	aaactctgtc	tgaagagatg	actcttgacc	tgtgtgtctc	1560
tggtgtaaaa	aagatgtcag	aaactttgcag	ttctgtgaa	ttttataaaa	atacaaaaaa	1620
ctttgtatat	acacagagta	tactaaagtg	aattatttgt	tacaagaaga	agagatgcca	1680
gccaggtatt	ttaaagattc	gctgctgttt	agagaatttg	tgaacaaagc	aaaacaaaac	1740
tttccagcca	ttttactgca	gcagctctgt	aactaaatgt	gtaaatatgt	ctggaccatt	1800
tttgcagcca	tgcaattgtat	tataacaag	actgaggtct	taaaatctgt	tcggacaatat	1860
ttactgtacc	ttactatttc	tgacaagact	tggaagaagc	ggagagatat	ctctgacatg	1920
tttgcagttc	actgcgaatc	ttttacatta	agccaaagat	tgaaaacatg	cttaaccact	1980

	agcaatcaag	ccacaggcct	tatttcatat	gtttctctaa	ctgtacaatg	aactattctc	2040
	atgaaaaatt	gctaaaaaaa	ttatattttt	ttctatttgt	agggtaaaaa	aaatacattt	2100
	gtgtccaact	gaataataat	tgtcatttaa	ataattttaa	agagtgaaga	aaattattgt	2160
5	aaagctcttt	gggtgcacat	gttatgaaat	gttttttctt	acactttgtc	atggtaagtt	2220
	ctactctctt	tctactcttt	tccactgtat	acagttgtct	gctttgacaa	agrtagctct	2280
	tattacttac	attttaaatt	cttatttgca	aaagaactgt	ttttatgggg	agaaacaaac	2340
	tctttgaagc	cagttatgtc	atgccttgca	caaaagtgt	gaaatctaga	aaagatttgt	2400
	tgtccacctt	gtttatttct	gaacagaggg	caaaagaggg	actggggcact	tctcacaac	2460
10	ttcttagtga	acaaaagggt	cctattcttt	tttaaaaaaa	taaaataaaa	cataaatatt	2520
	actcttccat	attcctctct	cctattattt	gtaatttaatt	tattttatga	taaaatttca	2580
	atgaaatgta	aatgtgttca	gcaaaattct	gctttttttt	catccctctg	tgtaaacctg	2640
	tttaataatga	gcccatcact	aatatccagt	gtaaaagtta	acacggtttg	acagtaacata	2700
	aatgtgaatt	ttttcaagtt	aaaaaaaaa	aa			
15	<210> 19						
	<211> 276						
	<212> DNA						
	<213> Human						
20	<400> 19						
	ctccctaaat	gattttaaaa	taaattggat	aaacatatga	tataaagttg	gtacttttaga	60
	aacccgcctt	gcattttttt	tatgtacaaa	tctttgtata	caattccgat	gttctcttata	120
25	tattccctat	atagcaaaac	aaaaccagga	ctccccaact	gcagctccca	agtcctctgt	180
	gagcactctg	ccaactggat	ggccctactt	gctttctgac	aaaatagctg	gaaaggagga	240
	gggaccaaat	aaatcactcg	gcgcgcacca	cgctgg			
	<210> 20						
	<211> 2361						
	<212> DNA						
	<213> Human						
	<400> 20						
35	attgtaccag	ccttgatgaa	cggtggccct	gcttcgcttt	tgagggccat	aagctcattg	60
	ccactctggt	tagaggctac	cttatcattg	tctcccgtag	ccggaaggtt	tctcccaagt	120
	cagagtttac	cagcagggat	tcacagagct	ccgacaagca	gattcttaaac	atctatgacc	180
	tgtgcaacaa	gttcatagcc	tatagcaccg	tctttgagga	tgtagttgat	gtgcttgctg	240
40	agtggggctc	cctgtactgt	ctgacgcggg	atggggcggt	ccacgcactg	caggagaagg	300
	acacacagac	caaatctggg	atgctgttta	agaagaacct	atttgagatg	gcgattaaac	360
	ttgcacaagc	ccagcatctg	gacagtgtat	ggctggccca	gattttcatg	cagttatggg	420
	accatctcta	cagcaagggc	aaccacgatg	gggctgtcca	gcaatatact	cgaacattgt	480
	gaaagtgtga	gccatcctac	gtgatccgca	agtttcttga	tgcccacgcg	attcacaacc	540
	gtgctgccta	ctgcacgacc	ctgcacgcag	aatccctggc	catcacccag	catcacacc	600
45	tgctctctaa	ctgctatacc	aagctcaagg	acagctcgaa	gctggaggag	ttcatcaaga	660
	aaaagagtga	gagtgaaagt	cactttgatg	tgagagacgc	catcaaggct	ctctggcagg	720
	ctggctacta	ctcccatgcc	ctgtatctgg	cggagaacca	tgacatcatc	gagtggtacc	780
	tgaagatcca	gctagaaagc	attaagaatt	atcaggaaag	cccttcgatac	atcgggaagc	840
	tgctctttga	gcaggcagag	agcaacatga	agcgctacgg	caagatctct	atgcacacca	900
50	taccagagca	gacaaactcg	ttgctgaagg	gactttgtac	gcacatgagt	ccagcctcgc	960
	aaggcccgag	cgataggagg	gcccaggctg	gcagggccaa	ctctgaggag	ttcatcccca	1020
	tctttgcca	taaccgcgga	gagctgaaag	ccctctcgta	gcacatgagt	gaagtgcagc	1080
	cagaactcacc	ccaggggatc	tacgacacac	tctttgagct	gcgactcgag	actgtggccc	1140
	actgaaagga	ttccacaggtc	aaagagaagc	tgccacgaga	ggccattttcc	ctctgaagta	1200
55	gtggtcgctt	ctgcgcagct	tttgacaagg	ccctggtctc	gtgcccagatg	cacgaactcc	1260
	aggatgtgtg	ccctttacct	tatgagcagg	ggaagctgtt	ccagcagatc	agtcactacc	1320
	acatgcagca	cgagcagtag	cggcaggtca	ctagcgtgtg	tgagcgccat	ggggagcagg	1380
	accctctctt	gtggggagcag	gccctcagct	acttcgctgc	caaggaggag	gagtgcaagg	1440
	agtatgtggc	agctgtctct	aagcatatcg	agaacaaaga	ccctcatgcca	ctctctctag	1500
60	tggtgcagac	cgtggcccac	aactccacag	ccacatctct	ccctcatcag	gactactcgg	1560
	tccaaaaact	acagaaacag	agccagcaga	ttgcacagga	tgagctcgcg	gtgctggcgt	1620
	accgagagga	gaccaaccgt	atccgcagag	agatccaaag	gctcaaggcc	agtcctaaga	1680
	tcttcacaaa	gaccaacgtg	agcatctgta	acagtgctct	ggagttgccc	tcagtcacct	1740
	ttctgtgtgg	ccactctctc	caccaaacat	gctttgagag	ttactcgaaa	agtgatgctg	1800
65	actgcccacc	ctgctctctc	gaaaaccgga	aggtcatgga	tatgatccgg	gcccagggaac	1860
	agaaaccgga	tctctatgat	caattccagc	atcagctcaa	gtgctccaat	gacagctttt	1920

	ctgtgattgc	tgactacttt	ggcagaggtg	ttttcaacaa	attgactctg	ctgaccgacc	1980
	ctcccacagc	cagactgacc	tccagccttg	aggctgggct	gcaacgcgac	ctactcatcg	2040
	actccaggag	ggcgcaactaa	gcagcctgga	ggaagatgtg	ggcaacagtg	gaggaccaag	2100
	agaaacagaca	caatgggacc	tgggcgggcg	ttacacagaa	ggctggctga	catgcccagg	2160
5	gctccactct	catctaattg	cacagccctc	acaagactaa	agcggaactt	ttctctttcc	2220
	ctggccttcc	ttaattttta	gtcaagcttg	gcaatccctt	ctctctttaac	taggcaggtg	2280
	ttagaatcat	ttccagatta	atggggggga	agggggaacct	caggcgaacc	tcctgaagtt	2340
	ttggaaaaaa	aagctggttt	c				
10	<210> 21						
	<211> 179						
	<212> DNA						
	<213> Human						
15	<400> 21						
	agggtgttaga	tgctcttgaa	aaagaaactg	catctaagct	gtcagaaagt	gattctttta	60
	acaatcaact	aaaggaactg	agagaaacct	acaacacaca	gcagttagcc	cttgaacagc	120
	tttataagat	caacgtgaca	agtgaagga	aattgaaagg	aaaaaattag	aactaatgc	
20	<210> 22						
	<211> 905						
	<212> DNA						
	<213> Human						
25	<400> 22						
	tttttttttt	ttctttaacc	gtgtggttct	tatttcagtg	ccagtggtac	agatacaaca	60
	caaatgttcc	agttagaagg	aattcaaacg	gaatgccaa	gtccaaagca	ggctcaagaa	120
	ataaaaaagg	aggtttggag	taatatagata	gatgactcca	atactactct	ttctcaaggg	180
	caaaaggtact	ttttgatcac	agttctgatc	ttgaaacttg	tgaaactctt	ttccaacctat	240
	taccatagtt	caaacaggca	agttatgggc	ttaggagcac	tttataaatt	gtgggtggga	300
	taggtgtcatt	aataactatg	aatatatctt	ttagaagggt	accattttgc	acttttaaagg	360
	gaatacaatt	tgaaaaactt	ggagactatt	catgactaca	gtcaagaagt	ggcgagaagg	420
35	gggagctgga	agagccttgg	aagtttctat	tacaaataga	gcaccatatt	cttcatgcca	480
	aattctcaaca	aaagctcttt	ttaactccat	ctgtccagtg	tttacaataa	aactctgcaag	540
	gtctgaccag	ttcttggtaa	caaacataca	tgtgtgtgtc	tgtgtgtata	cagcaatgca	600
	cagaaaaagg	taccaggagc	ctaattgcctc	tttcaaacat	tggggggaacc	agtagaaaaa	660
	ggcaggggctc	cctaattgtcc	attattacat	ttccattccg	aatgccagat	gtttaaagggt	720
40	cctgaagatg	gtaacccagc	tagtgaggaa	taaatacccc	acctgtgccca	gtccacagag	780
	aaacaacagt	agaaaagaag	ggcaactctt	tgctgcagag	acaaagttag	tgttttttcg	840
	ccatggattg	cagtcctctc	ctccagacca	gctgcttatt	tcctcagggg	cccagggaat	900
	gttga						
45	<210> 23						
	<211> 2134						
	<212> DNA						
	<213> Human						
50	<400> 23						
	ggtctcttct	ttcttttttt	tttttccaaa	agtggtcttt	tatttctagt	aacatatatt	60
	gtataaatac	tctatttttat	atgcacttcc	acaaaagcga	tataatttaa	aagttttttt	120
	cattagaaat	aaatgtataaa	aaataaatat	gttattatag	gcattttata	ctaactatag	180
55	tccttctctg	aaggaaacacc	caaaccaata	cttataaagt	acatgtaatt	tatagttaac	240
	tattttacta	tatacatatg	gaaaaaatca	tattctocaa	gaagagctga	acagacattc	300
	accaggatag	gactctttgga	ccagctgctg	gagatggacc	tgtaccacct	cagcagcttc	360
	cccaccacaa	gacaagtgtat	ctcaatgtcc	ccaaacctgt	gggaccctgt	ctcacacacc	420
	tcattttttg	tcggcggttt	catctctctt	gtgtgattgt	actgtatttc	atgagacaca	480
60	agttactctt	ttacatccat	attcccaaac	cagggtttaca	gtgtaggaaa	gaaggaaggt	540
	tggaaggtat	aagctcattg	tgtctctctt	agctttttacc	agcatctaat	gcttctactgc	600
	tttttttcca	ttgtagacct	taatgcactt	gaataaatac	atggagttgt	tttttctcca	660
	aaatgaatta	cacaaataaa	gactgagatg	gtccaaaaaa	ggaagaggga	agccatttgc	720
	gttatttccg	gttctgtgagc	ctttctctca	tgttgaaaca	tctgaagttt	taattctcgg	780
65	tagaaaaaat	gtataaacat	tctctgaaac	catagcagcc	ataaacagtg	ctgggtcaag	840
	atctattttg	tactctcttc	tccccccatt	gttagtgagg	taaaagtataa	caggtcttag	900

5 taaaaatctca cttttctcct acttttccatt tcccaacccc catgatacta agtatttggat. 960
 aagtaccagg aaacagggggt tgtaaatagtt ctaacttttt ttgacaattgt atttggtttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccg ggttttata 1080
 tgctatatca ctgctcagag gtaataaatc ctactaact atccatataa atttgaact 1140
 ggacgttttac tctgtatgt caactccttt tctatctacc ccataaatcc acccttactg 1200
 atacacctca ctggttactg gcaagatagc ctggatccct ccagccttct tgccttccct 1260
 gacacagccc ttctcactt tgccctggcc tcaaaagttaa caccacttaa accactaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgttttagg tttcttttaa ggatcacagc 1380
 10 tctcatgaga taacacccct ccactcatgg acagacactt caagctctct ttttgttaac 1440
 ccttccocaca gggtcttagaa catgatgacc actcccccag ctgccactgg ggccaggat 1500
 ggtctgcaaa agtctcgggt ctggctgggt tcaacttctt tcaactctcg gaagcagct 1560
 gtccatttaatt gctctggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattctgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 15 ccttctctctt ctttaacgaag taggtgtatt taatttttagg tgggaaggca ttgccccag 1740
 taagaacctg gatggtcaag ggctctttga gagggctaaa gctcgcaatt ctttccaatg 1800
 ccgcagaggga gccgctgtac ctcaagacaa cactcttgta cataatgtct tgccttaagg 1860
 tggacaagaat gtatgcacca ttaagaatat atgtgccaac agcagctttg atggcaagaa 1920
 agctgcgaatt gttcctggat ccctctgggt cactctggtt cactctgagt tgggtgtctc 1980
 20 cagttggaat tgtgatata tcatgatata caggttttgc actagtaact gatcccgata 2040
 tttttttaca agtagatcca tttcccccgc aaacaccaca tttatcaaac tcttttttgg 2100
 agtctatgat gcatcacaa ccagctttta caca

<210> 24
 <211> 1626
 <212> DNA
 <213> Human

<400> 24

30 ggacaatttc tagaatctat agtagtatca ggatatattt tgccttaaaa tatattttgg 60
 ttattttgaa tacagacatt ggtcccaaat ttcatctttt gcacaatagt atgaactttc 120
 actagaactt ctaaacattt gggaaacttt caaatatgag catcatatgt gttaaaggctg 180
 tatcatattaa tgctatgaga tacattgttt tctccctatg ccaaacagggt gaacaaacgt 240
 agttgttttt tactgatact aaatgtttggc tacctgtgat tttatagtat gcacatgtca 300
 35 gaaaaaggca agacaaatgg cctctgtatc tgaatacttc ggcaaaccta ttgggtcttc 360
 attttctgac agacagattt tgactcaata ttgttagagc ttgtgtagaa ttgattacat 420
 ggtagtcatg cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480
 aatccttttat gttcttttat tghtaagcata tctgaaatta ctttataaag atggttttag 540
 aaagctttgt ctaaaaattt ggctcaggaa tggtaacttc attttcagtt gccaaaggggt 600
 40 agaaaaataa tatgtgtggt gttatgttta ttttaacata ttattaggta ctatccatga 660
 atgtattttca atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccattttagcc cagtgaggaaa gtcttggaac tcaggttacc ctggaaggat atgctggcag 780
 ccatctcttt gatctgtgct taaactgtaa tttatagacc agctaaaatcc ctaacttggg 840
 tctggaatgc attagttagt cctgttacca ttccagaat ttcaggggca tctgtgggtt 900
 45 ggtctagtga ttgaaacac aagaacagag agatccagct gaaaaagagt gatccctaat 960
 atctcaacta actggtctctc aactcaagca gaggttcttc actctggcac tgtgactatg 1020
 aaacttagta gaggggattt tgtgtatttt ataccaattt aatacaatgt ctacattaga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattca atcatattag 1140
 50 aactaaagta tttatctatg aagataataa tgggtgcagag agactttcat ctgtggattg 1200
 cgtgtttctt taggggtctc agcactgatg cctgcacaaag catgtgatat atgctggcag 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggtac tgcaatcaca 1320
 atgccaagat gtgtttatgg gctatttggg taagtaagtgt atgaagtact atgaagtaag 1380
 tgtgttttgt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440
 55 tgggtcaata tttgtcattt caactttgca ttgaaattga attttgtgt atttatagt 1500
 attataacctg tcaagcttct agttgtctca accattttat aaccattttt gtacattatt 1560
 tacttgaaaa tatttttaatt ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620
 aaaaaa

<210> 25
 <211> 1420
 <212> DNA
 <213> Human

<400> 25

65 gtccagcatt gtttctgctt ctgaaatctg tatagtacac tggttgttaa tcatatgtc 60

5 ttcattgaaa tccctgtctac ttctcttctc cctcaatgaa agacacgaga gacaagagcg 120
 acacaagcctt aagaaaaaacg agcaagggaag agtatcttca ttattctctat ttctctctgag 180
 ttggaaaacaa aaacatggaag gactccaact agaagacaga tatttaccatt taaatagatt 240
 agtgggaaaaa ctttaagagt ttccacatat tagttttcat ttcttgagtc aagagactgc 300
 tccctgtactt gggagacact agtagtatat gttgttaatg ttactttaaa attatctttt 360
 tattttataa gggccataaa tactggttaa actctgttaa aagtgggccc tctatcttct 420
 atgggttcac tggccatcagc catgctgata tattagaaat ggcattcccta tctacttact 480
 ttaattgccta aaattataca taaaatgctt tatttagaaa acctacatga tacagtgggt 540
 tcagccttgcg catgtatcag ttctacttga aatttgagac caattaaaatt tcaactgttt 600
 10 aggggtggaga aagaggtact ggaaaaacatg cagatgagga tatcttttat gtgcaacagt 660
 atccttttga tggaggagga gttactcttg aaaggcaggc agcttaagtgt gacaatgttt 720
 tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780
 tttgctctgt tttgctgaa gtttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840
 15 accagtacct ggggaggtta gatgtgtgtt tcaggcttgg agtgtatgag tggttttgtc 900
 tttgctctgt tttgctgaa gtttttagtat ttgttttcta ggtggacctc tgaaaaccaa 960
 gtggctttgt tttttttct caagtaaaat tgtgaacata ttctcttat aggggagagg 1020
 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080
 tgcacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttgggt aggttactgt 1140
 20 acatcaaatc atgcataaat ggcagcttgt ttcttggagc cactgtctaa attttggttt 1200
 tatagaaatt ttttatactg attggttcat agatggtcag ttttgtacac agactgaaca 1260
 atacagcaat ttggccaaaaa tgaggtgagc attgtttaaa cttgtgtgtg taacactgt 1320
 tctttgtaat tgggttgtgg tgcattttgc actacctgga gttacagtt tcaatctgtc 1380
 agtaaatataa gttgtccttta acttcaaaaa aaaaaaaaaa

<210> 26
 <211> 689
 <212> DNA
 <213> Human

<400> 26

35 aacacaaacaa aaaaaaaagt agtactgtat atgtaaatag tagcttttca atgtgtctata 60
 aaacaaatta tagcacactcc ttccctttac ttgtgtctac ctcccttagg tgagtacttc 120
 ctttaataagc tgcataaacat acatatacgg aacttgaaag ctttggttag ccttgccctta 180
 ggtaatacagc ctagttttaca ctggttccag ggagtagttg atttactata aaccattagc 240
 cacttgtctc tgcacacatt atcacaccag gacagggctc ctcaacctgg ggcgtactgt 300
 cacttggggc caggtgtatt ttccctgcaa gggctgtctc gactgtgcc ggccggcgc 360
 tgaagagctg gtcggggccc aggtactgaa aggacacaag ggcctgtgct gacctcagg 420
 40 attccaaatg atccaaaggaa caaagcttca gggctctggg ttgtgtctcc cactattcag 480
 gagggtgttg gaggttaacgc agcttcatat cgtccagtc ttctcagat ttaaaagtgt 540
 tgtccaagat ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600
 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctctgaa tagtgggaga 660
 cacaccocaga gcttgaagtt tgtcctctcg

45 <210> 27
 <211> 471
 <212> DNA
 <213> Human

<400> 27

55 tcccagcggc atgaagtttg agattggcca ggcctgtac ctgggcttca tctcctctgt 60
 cctctctcgt cattggtggc acctgtcttt cctgtctctg ccaggacag gcaacctata 120
 agccctacgt caggcccccgc ccaggccacac cagcaccact gaaacacagc caactgccta 180
 ccagccacaca gctgcctaca aagacaatgc ggcctctca gttacctgc ccaaccacag 240
 gggtaacagc tgaagactca cgtgtgagtc gccacagct tggctctccc tggctctgt 300
 tgggctgggt cccggcggga ctgtcaatgg aggcaggggt tccagcaca agtttacttc 360
 tgggcaattt ttgtatccaa ggaaataatg tgaatgcag gaaatgctt tagagcacag 420
 60 ggcagagagg ggaaataaga ggaggagaaa gctctctata ccaagactg a

<210> 28
 <211> 929
 <212> DNA
 <213> Human

<400> 28

5 ggtgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60
 gctgctctcg acgggttggc tgctgggtgg ctttccctc actgtcattg gaggcattct 120
 tgggaagaac aacgcagacc cctttgatgc accctgtcgc accaagaaca tcgcccggga 180
 gattccaccc cagccctggt acaagtctac tgctatccac atgactgttg gagcttccct 240
 gccctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtaccat ttgtacggca tctctctctt tgctctcgc atctctgtga gtgtgggggc 360
 ttgatctccc attgcaacta cctacttcca gttgtctggg gaggattacc gctgggtggg 420
 10 gogatctctg ctgagtggtt gctccacggg cctctctact ttctctact cagtcttcta 480
 ttatgcccgg cgctccaaca tgtctggggc agtcacagaa gttagagttct tcggctactc 540
 cttaactcact ggttatgtct tcttctcat gctgggcacc atctctact ttctctctg 600
 aaagtctcat cggtatatct atgttaacct caagatggac tgagttctgt atggcagaac 660
 tattgtctgt ctctcccttt ctctcatgcc tctaccagc ttctctctg 720
 15 attgaactga ttgtgtgatg gcattgttgc cttccctttt tccctttggg cattctctcc 780
 ccagagaggg cctggaaatt ataaatctct atcacataag ctatataat tgaactcttt 840
 taagtgtcct ttagtttttg tctgtatttt tctttttaca attacacaaa taaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

<210> 29
 <211> 1775
 <212> DNA
 <213> Human

<400> 29

25 gaacgtgatg ggaactttgg gaggatgtct gagaaaaatg ccgaagggat tttggccaac 60
 accagaaaaa gccaatgtcc taggaattcc ctcccaaat gcttcccaaa aaattactca 120
 ttgacaattc aaattgacct tggctggcgg cagcccgggc ggcccttcagt ccgtgtgggg 180
 30 gcccccggtg gcccttctct cttaggacct cccaactcgc ttcaactctgc gtttatccac 240
 aggataaagc caccgctggt acaggtagac cagaacaccc acgtctgtcc ggaagcaggc 300
 cagccggtga gacgtgggca ttgtgatgat gaaggcaaa acgtcatcaa tgaaggtggt 360
 gaaagctctg taggtgaagg ccttccaggg cagagtgtcc actgttagtt 420
 35 cacaaagctg tggggcagca tgaagaggaa accaaaggca tagaccocgt tgaagaaagt 480
 gttgattaac caggagttacc agctcttata ttgtatttc agagtgtaat agacagcacc 540
 cccagcacag agaggggtaca gcaggtatga caagtacttc atggcgtgag tatcgtactc 600
 ctccgttttt ctctcagatt cgctgttaagt gccaaactga aatctcggtga cctgtctctc 660
 ccaaaaaata gtcattctca atgccttctt cactttccac agctcaatgg ccggtccaac 720
 40 acccccgggg accagaccca gcaggtctgt cgtctgtgcc agcaggaaaca gaaagatgac 780
 cagcgtgctg aagcagcgcc agagcactgc cttggtggac atgcgatca tgctcttctt 840
 ctctcttcgg aaactgatgt catttttaaa ggccaggaaa tcaaaagaaa gatggaaagc 900
 tgcgacaaga aaggtcagcg ccaggaaatg taagtgtgta tctacaaaaa tctcttccac 960
 ctcatcagca tctttctctg aaaaaccgaa ctgctgcagg gactgtcagg agtctctgat 1020
 45 tgggatacag aagcgcagcc gccccagtga gacctgtcg taggacacag tgagggggag 1080
 ctccgtgggt gagcgtt tta tgaccatcag gtccttcacg ccgtgtgctga ctggtctgat 1140
 gaacaggatg ggcaggtaat gcacggtttt cccacgctgg atcatcttca tgacaggtat 1200
 cacatcggca ggcaggagg acccgtcaaa tccggcatca tccggcatca cgtctdggcg 1260
 cagcccgctg cgccagtggt acactggctc atccagggca ctctgtcgtt cttctctcgc 1320
 ctogatctg ttgtgtacag actcccgggt gacaggtgtt atttctctg cgtgtgggac 1380
 50 catgtaggtg gtcagaggac tgaccaggtg caactgcttc ccgtcgtgcc accgcaggac 1440
 cccagcgtga tggaggaaga ttaggcata gactctcca cctttctctg ttctctttgg 1500
 tacagaaaca ttaactgtcc ttcaaaatt ggactccaca tcaaaagtctt ccacattcaa 1560
 gaaccagctg atgttgttct cagcaccacag gtgggacctc gctgtgtgtg acacgtcag 1620
 ctgcagctgt ggcgcgcgc caggtagagg ctggatgcag ttggcgtcgc cggagcagcg 1680
 55 gcgggtgtag acagtccgt acatgacca gcaggtgtgc accacgtaga ccacgaacac 1740
 gccaccaccc aagctggtga aggagctgag gccccc

<210> 30
 <211> 1546
 <212> DNA
 <213> Human

<400> 30

65 aaaataagta ggaatgggca gtgggtattc acattcacta caccctttcc atttgtaaat 60
 aaggccctgc caggctggga gggaattgtc cctgcctgct tctggagaaa gaagatattg 120

	acaccatcta	cgggaccat	ggaactgctt	caagtgaacca	ttctttttct	tctgccagat	180
	atttgacaga	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaac	catctataac	aacaccaaac	acagaaatcat	tacagaaaaa	tggtgtccaca	300
	ccaacaaactg	gaaacaactcc	taagggaaca	atccccaatg	aattactctaa	aatgtctctg	360
5	atgtccaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaaagccac	aacccatgat	420
	gtcagaaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgttttcaa	cattacaaga	ttccaaaccc	aagactgaaa	ctcagagttc	aattaaaaa	540
	acagaaatac	caagtagtgt	tctacaacca	gatgcacac	cttctaaaaa	tggtacatta	600
	acctcaatac	cggttacaat	tccagaaaaa	acctcacagt	ctcaagtaat	aggcactgag	660
10	gggtgaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgcgc	720
	gtgggtattg	ctttgattgt	aataacaact	tcagtatttg	tttgggtggg	tttgtaccga	780
	atgtgttggg	aggcagctcc	gggcacacca	gaaaattggaa	atgatcaacc	tcagctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaattcttc	atgagctcgg	tgagcactct	900
15	acacaaagaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcactaat	960
	tacgtctta	cttcagcttc	tatgcaccaa	gggtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatcccgact	tcataacctg	ctgctggact	gtaccagacg	ctgttcccg	taaaagtgat	1080
	tcacagctga	atgcaataat	ttgatggaa	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttta	aaattccatt	actccattta	caggagcgtt	ccctagaaaa	ggaaatttag	1200
	gaggagaaat	tgtagcagct	gaattctgac	gcccaggagg	tggtgctcgt	gataggcatg	1260
20	actttctcta	actttttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	ctttttctcg	tggttctata	ttactactgt	ttagtattta	ttgtttacac	ctatgttaat	1380
	gcagggaaaa	gtgtcagctg	tattattaaa	tattaggtag	aaactcatcc	atgctacttt	1440
	gtacatataa	gtattttatt	ctcgtcttcg	tggttacttt	ataataaac	tactgtactc	1500
	aataactcaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		

<210> 31
 <211> 750
 <212> DNA
 <213> Human

<400> 31

	cacttgggca	ccccatttt	ctaaaaaaat	ggaatctg	aggcgcaaaa	agggtgctg	60
	aagggaatg	ccctctgatg	ccccaaaacc	ttcttccaaa	ctagtgtagg	aatggaatg	120
35	atcgcaaatg	gatccctttt	ggcctccttt	ggagcatgcc	ttccctatct	tatcctgtgc	180
	ccacaaagag	cgacaagctta	cggatatctt	tgtttttgcc	atggtagtgc	ttcttggcca	240
	aaacagcctt	ccctaattgg	aaaatgcagt	cctgtttaaa	acctttgat	tacgactact	300
	tgtagactgt	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
40	cagtgaacaa	tgacaagatc	ataaagaaca	gtatcatatt	attattttag	cgcttttaca	420
	gtggcaacgc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcag	tgagtataac	480
	ttttaaatag	ttcctcagca	cactatttcc	catgcattaa	atatgataaa	ataactctac	540
	actgcccact	ggctctgttaa	aaagggaagt	tgaatacaga	ggccacacaa	ctaaaatgtg	600
	ttttctagct	acaaagtata	gcatacatca	ccagacacag	atttggactc	cctgcacagg	660
45	ggattggaaa	acgggtgtta	aagagaagag	aacattttta	catataatgt	atgaagaatc	720
	ccaaaggcct	tatttctgac	cacgctccgc				

<210> 32
 <211> 1620
 <212> DNA
 <213> Human

<400> 32

	gcaattcccc	ctcoccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
	gtgcagccat	tcataagaac	cttggtgccc	cagaaaaaat	tgctcctttt	ggtagcaaac	120
55	ctgaggtctt	ttgggaagata	atgtagaaaa	ccactacctta	ttgaaggcct	gttttgggcta	180
	atctgtgcac	actctgatga	tacctgcctt	atgtggattc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgtcttta	caataaatta	aaagtatgtg	300
	atgttctggg	ttttttcctt	cttttttagaa	ccccgcctcc	atttataaaa	ttataaaaaa	360
60	aaaaaaaact	tttaacattt	aaaaaataaa	aattatacaa	atttcactta	ttccaggaca	420
	cgctggcatt	tggaactcaat	gaaaaggcca	cctaagaaga	ataagggtga	ctgaatgttt	480
	tcacataatt	tcgacacata	acagtcctct	ttctatccag	ttgccttcca	tttactctta	540
	gggtgtgact	ttcaggaacac	atccttggtc	attgcccaga	aagtaactga	gctaactagt	600
	atttgaatgg	cacagggaac	cgaatcacat	gggtgccttc	cccttggttt	tcgaagtact	660
65	tggaagtgtg	cacaaaaaatt	aggctcatgc	ttcagtgctc	tgctctttta	acctaccctt	720
	tgacaaactc	gtgcataatga	ttgtatacta	ttaaaaccag	catataagta	ttgtaaatgt	780

gtgttctctc taggttgga gaaatgtctt tcttctctac tgggtctctg taaagcgggt 840
 gtcagttgtg tcttttcacc tctgatttgg aattaataga attgggggga gaggaaatga 900
 tgaatgtaac tagtttccag ttttggcatg atcatcttc tctcactttg 960
 5 tgcgaacatc gcccttatcg taagaacaag ttccagaaat ttccctccac tatcagactc 1020
 cagttatttg tttaacaacc attggatgag tgcagcatta taagaccttg gtgccagaa 1080
 aaactgtctc tttttgtgac caaacctcag gtcttttggg agataatga gaaaaccact 1140
 accatttgaa ggcctgtttt ggctaactct tgcaaacctc gatgatact gcttatgtgg 1200
 10 attcttttcc acactgcttt catttttaag tataaagact tagaanaact gaataatgct 1260
 tttaacaata atttaaaagt tgtgatgttc tgggtttttt cctctttttt agaaccctgt 1320
 atttaaacaa gccctctttt taagtctgtt ttgaaattta agtcttcagat cttctggata 1380
 ccaaatcaaa aaccacaacg gtaaaaacag gcagttattg tgttcttaat tttaaaacct 1440
 tttatgtata tctacataat atagatgcac aaacaacact tcccttttag tagcacatca 1500
 accatagata ttgtacatta caatgaaat gtgtaactta aggttattat atataaat 1560
 15 acatatatata ctttgttaacc ttttactgtt aaataaaaaa gttgctttag tcaaaaaaaa 1620

<210> 33
 <211> 2968
 <212> DNA
 <213> Human

<400> 33

gaaaaagtga aaggaacac agttcatata gaagtaaaag aaaacctga agaggaggag 60
 gaggaggaag aagaggaaga agaagatgaa gaaagtgaag agggaggaga agaggaggga 120
 25 gaaagtgaag gcagtgaagg tcatgagaga gatgaaaagg tctcagatga gaaggaatca 180
 gggaaagacat tagataaaaa gccaaagtaa gaaatgagct cagatcttga atatgacctc 240
 gatgatgtac ggactaaaga aaaaagggct tatgacaaa caaaacggag gattgagaaa 300
 cggtgacttg aacatagttaa aatgttaaac accgaaaagc taagagcccc tattctctgc 360
 30 gtactttggc atgtggcac agggagaca aaaattctag ataagctcgc tcacacacat 420
 gtacaagatg tgaagcagg tggatcacca caacaaattg gcgccaccaa tttctctctg 480
 gaagctattt atgaacagac taagatgatt aaaaaatttg atagagagaa tgtacggatt 540
 ccaggaaatg taattattga tactctggg catgaaatct tcaagtaatc ttattctctg 600
 ggaagctctc ttgtgacat tgcactttta gtgtgtgata ttatgcatgg ttggagccc 660
 35 cagcaaatgt agtctatcaa ccttctcaaa tctaaaaaat gtcccttcac ttgtcactg 720
 taataagatt ataggttata tgattggaaa aagagctcgt actctgatgt gggtgctact 780
 aaaaaaagc agaaaagaa tacaaaagat gaatttggag agcgagcaaa ggtctattatt 840
 tagaattttg cacagcagg ttgttaagct gctttgtttt atgagataaa agatccccgc 900
 acttttgtgt ctttggtagc taacctgca catactgggt atggcatggg aagctgtatc 960
 40 tactctcttg tagagttaac tcagaccatg ttgagcaaga gacttgcaca cctgtgaagag 1020
 ctgagagcac aggttaggga ggttaaaagt ctccggggga tgggacacac tatagatgtc 1080
 attcttgatca atgggcgttt gaaggagaga gatacaatca ttgttccctg agtgaagagg 1140
 cccattgtaa ctcatagctc aggcctcctg ttacctctct ttcatgaagg attacagttg 1200
 aagaacccag atgaaaagca taagaagata gaagcagctc aggggggtaa gattcttga 1260
 45 aaagacccag agaaaacatt ggctggttta cccctcctg agacctgtat gaagcagtgaa 1320
 attcctgttc ttaaaagtga attgatccat gagttaaaag agacactaaa tgcatacaaa 1380
 ttagaagaaa aaggagctct tgcacaggca tctacactgt tctcttctat agctctactg 1440
 gaattttctg aaacatcaga agtgccctat gcaggaatta acattggccc agtgcataaa 1500
 50 aaagtcttga tgaagctctc agtgatgtt gaacatgacc ctagatgttt aggtattttg 1560
 gcccttcgat tgagaattga acagatgcca caagaaatgg ctagatgttt aggaagttag 1620
 atttttagtg cagaaattat ttatcattta ttgtgatct ttacaaaaata tagacaagac 1680
 tacaagaaac agaaacaaga agaatttaag cacatagcag tatcttccctg caagataaaa 1740
 attctccctc agtacatttt taattctcga tcatcgatga tgggtgggtg gcagggtgga 1800
 cgaggtcagg tgaacacagg gacacccatg tgtgtcccaa gcaaaaaatt ttttgacatc 1860
 55 ggaatagtag caagatttga aataaaacat aaacaagtgg atgttgcaaa aaaaggcaaa 1920
 gaagttttgt taataataga acctatccct ggtgagtcac coaaaaattt tggagacat 1980
 ttggaagcta cagataattct tgttagtaag atcagcggcg ctagactatg tgcactcaaa 2040
 gactggttca gagatgaaat gcagaagagt tactggcagc ttatttggga gctgaagaa 2100
 gtattttgaa tcatctaat ttttcacatg gactgagaaac tggagttaat gcaatctgtg 2160
 60 ttgttaatat ccccaaaaaa atcagacaaa aaatggaaac gactgtattt gacactgtgt 2220
 gacttaataa tgggaaggag aaaaataggt gtataaaatg gtattctatg gaaccaagaa 2280
 aacttaccact ggtttgacag tggctcagtta catgtcccca cagttccaat gtgcctctc 2340
 actcaacctc cccctcccca accctctctc acttggctgc ttgttcttaa gtttccctc 2400
 cccaaatttg gattttttat acagatctaa agotcttctg atttttact gattaaatca 2460
 65 gtactgcagt attgtatga aaaaaaaaac gcagattttg tgattcttctg gacttttttg 2520
 acgtaagaaa tactttctta ttatgtcata tcttcccac agtgattttt ccagacttct 2580
 tctgcacata gccctttagg cttttataaa atagaaaatt aggcattctg atattttctt 2640

5 agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt. 2700
 agtcacagagt ccatgtgaat catcacaaatt ctacacataa agaaaacagá 2760
 catccacagc taagcaagct ctgttaggctt tccatgggta ctctccaca 2820
 agttgtcttc ctagggacaag gaattatctt aacaaactaa acactacctt 2880
 ggtatggcag cactctggga acagtaggag attttataca ttaactctgat ctgtttaatc 2940
 tgatcggttt agtagagatt ttatacat

10 <210> 34
 <211> 6011
 <212> DNA
 <213> Human

<400> 34

15

20 acggggcgcc ggaacgacccg cacatcttat cctccacgccc ccactcgcac tccggagcggg 60
 acggcccgccg acctccccttc gggcccgccca ctcgaggagtg gaggagagag gccgcggccc 120
 cggcttgagc cgagcgcagc acccccggcg ccccgcgcca gaagtcttgt tgaaccggcg 180
 tgcggggaga aacttttttc ttttttcccc ctctccgggg agagtctctg gaggagggag 240
 ggaactcccc cggcccaagg ctctggggct cggggctcgg agcgcccgaga agggcggggg 300
 tccgcggcgg agggggcgcc ccccccggga ccgagagagg gggctgaggc cgcgggctgc 360
 tggtcgaggg cggcgacagt gtgcggcgcc caggggaggg tggctggcgt tcccgcccg 420
 tttggcgagg gaggggcgcc gggcgcgagg aggatgtact tggctggcgg ggacaggggg 480
 tttggcgagg cggcgacagt cctggtctcg ctgctggggc tgctgctgct gccggcgccg 540
 tccggcacccc gggcgctggt ctgcctgccc tgtgacagtg ccaagtgcga ggagccccag 600
 aaccggccgg ggaacatcgt gcaggcgctc tgcggctgct gctacacgtg ccgcagccag 660
 gggaaacgaga gctgcggcgg caccttcggg atttacggaa cctgcgaccg ggggctgctg 720
 tggctcatcc gcccccgcct caatggcgac tccctcacc agtacgaagc gggcgtttgc 780
 gaagatgaga actggactga tgaccaactg ctgtgtttta aacctgcga tgaaaaacct 840
 attgctggct gcaatataat caatgggaaa ctgtaagtta acacattgc aacctgcagc 900
 aatccctttg agtttccaa tcaggatatg tgcctttcag cttaaagag aattgaagaa 960
 25 gagaagccag attgctccaa ggcccgctgt gaaagccagt aacctgcagc aacctgcagc 1020
 gatctctgt tgcacgagg ttatgtctct cctggggagt ctgtctccct acccagccgc 1080
 tgcgtgtgca accccggct ctgtctgcgc aaagtctgcc agcgccgaaa cctgaacata 1140
 ctagtgtcaa aagcctcagg gaagccggga gagtgtctgt acctctatga gtgcaacata 1200
 gttttcggcg tggactcag gactgtggaa tgccctactg ttcagcagac gttgtctgac tttgccaa 1260
 30 ccggacagct atgaaactca agtcagacta actgcagatg gtgaggtgtg atccactccc 1380
 agatgcaggt gtctctcttg ctatgttgt tccccgtgt gtgaggtgtg atccactccc 1380
 cgcatagtct ctctgtggca tgggacacct ggaagtgct gtatgtcttt tgaatgtgtt 1440
 aatgatacaa agcocaactg cgtatttaac aatgtggaat attatgactg agacatgttt 1500
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcacccgc 1560
 35 cagtgtgggt agataaactg cgagaggtac tacgtgcccg aaggagagt ctctccacgt ctgccaagt 1620
 tgtgaagac cagtgtatcc ttttaataat cccgtcggct gctatgccaa tggcctgatc 1680
 40 ctgcccagcg gagacaaggt gccgggaagc gactgcacat ctgcccagt ctgccaagt 1740
 gaacgccact gcgttgcgac gtctcggga cagacctgca caaacctctg gaaagtgcct 1800
 ggggagtggt gccctgtgt cgaagaacca accatcatca cagtgtatcc accgtcatgt 1860
 45 ggggagttat caaactgcac ctctgacacg aaggactgca ttaattgttt caaacccgat 1920
 50 cacaattggt gtgcgacctg tcagtgcata aacaccagg acatagtctc acagtgtctc 1980
 caaggctgca ccttgaactc tcccttcggt ttccctactg atgcccacaa ctgtgagatc 2040
 tgtgagtgcc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
 ctctgagttg tgaagaataa ccacggctgt gacatctgtc ctgtgaagaa atgtccagag 2160
 55 ctctcatgca gtaadactct ccccttgggt ttccagcagg acagtgtctc ctgtcttatt 2220
 tgcgaagtga gagagggctc tgcctcagct gggccaccca cctctgctgg cacttctctc 2280
 accgtgtgat gtcactcatc taataatgag gaggctggtc acgtgtggtc ccgggaatgc 2340
 tactgtctca atggacggga aatgtgtgct ctgatcacct gcccggtgct tgcctgtggc 2400
 aaccocacag ttaacccttg acagtctgc ccatcatgt ccatcatgt cagtgtgct 2460
 60 aagccagagc tcaagtactc ctccatttgc caegccctgt gaggagaaat ctttgtggaa 2520
 ggaagaaagt ggaacattga ctctgtact cagtgcact gccacagcg accggtgctg 2580
 tgtgagacag aggtgtgccc accgtgtctc tgcgaagacc ctacagcac ccaggatctc 2640
 tgcctgccac agtgcataca tcaacctttt cggccttctc tgcctccgaa taacagcgt 2700
 cctaactact gcaaaaatga tgaaggggat atattctctc gactgagtc ctgggaagc 2760
 65 gacgttgtga ccaagctgat ctgcatgat agcgttaata ctgttttctc tgaagtctgc 2820
 cctctgtgat cctgtgaag acctgtctg agaaaaggcg agtgttgtcc ctactgcgt 2880
 aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgcgcagag 2940

5 gaggcggtggg accttgacag ctgcacccac tgcactgccc tgcaggcgcca gacctctgccc 3000
 tcgaccgctga gctgcacccc ctgcacccac tgcactgccc tgcaggcgcca gacctctgccc 3060
 tgcacaaatgt gtccagaaat gtatgtccca gaaccaacca atataccocat tgaagaagaca 3120
 aacatccagag gagaggttga cctgagggtt cccctgtggc ccacgcctag tgaagaatgat 3180
 attctgcata tccctagaga tatgggtcac ctccaggtag attcacagaga caaacagctg 3240
 caccacaagt aagattcttc actgactacc attgctccag ttgtgggtccc cataattata 3300
 tgcctctcta tctaataagc attcctattc atcaatcaaga agaaaacagt gataccaact 3360
 ctttgcctgt atcgaaaccc aactaagcct tottcccttaa ataactcagct agtatctgtg 3420
 gactgcacaaga aggagacacag agtccagggt gacagttccc agagaattgct aagaattgca 3480
 10 gaccacagatg caggattacc ttggctctcac agcatgcaaa acagagaacca tctacaggca 3540
 gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600
 gacgactaaa tctgtctcaa aaagtaaacct agaatttgtg cacttgctta ttggattgta 3660
 ttggattgtg acttgatgta cagcgctaaag accttactgg gatgggctct gtctacagca 3720
 atgtgcagaa caagcattccc cacttttccc caagataaact gaccaagtggt tttcttagaa 3780
 15 ccaaggtttt taaagtgtct aagatatatt tgcctgtaag atagctgtag agatatttgg 3840
 ggtggggaca gtgagtttgg atggggaaag gtgggtgggg cagttgttgg gaagaaaaat 3900
 ttgctgacgtt ggctcgggga gaaacccgtgt aacataaaag cagttgttgg gccacaggt 3960
 ttttttttct ctattgtctc gaagactgca ctgggtgctg caaagctcag ccttcacaga 4020
 20 gcaggaaaca aaaaaggcct tgcgacccag agtccataac cactctagaa ctaccagcag 4080
 agcacatcag aaccttttga cagccatccc aggtctaaa gcacaagttc tttcttata 4140
 cagtcacaaac tgcagtggc agtgaggaaag ccagagaaat gcgtagcgg ctttcttata 4200
 aagcgggtta ttaaggatat atacagttac acttttggct gcttttatt ttttccaaagc 4260
 atcatcaatca gccagtttct agcagagtca gcacatgaac aagattctaa gtattcttgg 4320
 25 cttgtgacac ttggagctttt ttttttaca acgtgacagg agaggagggg agaggggggg 4380
 gaacaccagg catttccagg ggctataatt tctagcttaa tggttgttgg tctgttata 4440
 ttgttgggtg tctatagttt ttgttgaagc tctagcttaa taaagaaact ttttaaaaa 4500
 gactgttttg ggattcttct tcttatttat atactgattc taaaaaatag aaactcttcc 4560
 attttaattg tatattattc aagcaccttt gtgaaagctc aaaaaaaatg atgcctcttt 4620
 30 aacttttagc taattataga gtatttatgt aactatctta tgcctcaaaa acaaaaagta 4680
 ttgtgtgtga ttgttatata atatatatat atacatatat atttatacac atacaattta 4740
 tgttttctct tttgatttat ttttatgaga ttttaaccag aacaaaggca gataacagg 4800
 ctctccatag cagtgtcttt gatcacttac aaattttttg atatacaca aattctatc 4860
 tacttccagt taatttgaaa agatgtgtgt gtgagagat gtatgtgtgt gtgtgtgtgt 4920
 35 gtgtgtgcgc gcgcagcac gccctgagca gctcagattg gtcagcattg caccgtgcat ggagaagggt 4980
 attcctctga taaaattctc ctcatattga ttgtcttcca gttgttttcc atgtgtctcc 5040
 ctggccagag acattgatgg cagtttttat ctgcactcac atcagctccc tggatttttt 5100
 tttttttttt tcaaaacagt gtttgaacaa actactggaa tatgttccac aataagctgg 5160
 aagtttgggt tagtatgcct caaatataac ctatagtgta ctatagtgta attagtttt 5220
 40 acagccctta gccactttat actaattaac ccatttggc attgagttt ctttataaaa 5280
 tgcctgttgt gaaagacaca gataccaggt atgcttaacg tgaagaaaga attgttctgt 5340
 ttttttaag gaaactttca gtattgttgt aaatacttgg acagaggttg ctgaacttta 5400
 aaaaaattat attttattat ataagacct aatttattaa tctgaagatt aacctatttt 5460
 ttgtcttata atttcaaaaa gaaaagaaaa aaggtgttct agctgtttgc atcaaaaggaa 5520
 45 aaaaagattt atttacaagg ggcaatat ttattctttc caaaaaaat ttgttaatag ttttataatg 5580
 tacattacaa aaatagattg acatcagcct gattagatata aatttttgggt gtaatttaac 5640
 ctactctctg ataaaaagtc ttatcaaaaa aattgttctg atgttctgtt ttgttttttt 5700
 caatcatggc catatattga aaatactaac aggatattag acaaggtgta aattttttta 5760
 ttattatttt tttatcctga ttatcctgtg ttgctgtatc ttactctctt tacttctgtg 5820
 50 tctctgtgtg ctcttgtaaa agaaaaatat aatttctgta agaatataat agtatatagg 5880
 cacttggagt gcactcagtg tctacagttt gttttggtt ttctcaaaaa agcgtgatag 5940
 gaattatctg caacttgatt ctgtggcagga aataaacatt ttgagttaa atcaaaaaa 6000
 aaaaaaaaaa a

55 <210> 34a
 <211> 1036
 <212> DNA
 <213> Human

60 <400> 34a

65 mylvagdrgl agcglllvs lglillpars gtralvcipc deskceprn rpgsivgvvc 60
 gcocytcasq nescggtfgi ygtodrglrc virpplngds lteyegavce denwdtdqll 120
 gfkpcnenli agcnliingkc eentirtcsn pfefspqdmc lsalkrieec kpdcskarce 180
 vqfsprcped slwiegyapp geccpplsrc vcnpagclrk vcpgnlnil vksasgkpgc 240

ccdlieckpvp fgvdortvec ptvqgtacpp dsyetqvrllt adgccttlpr cecisglogf 300
 pvcevgstpr ivsrgdgtg kcdvfevnn dtkpacvfnv veyydgdmfr mdcrcfrccq 360
 ggvalcftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglll ahgdrwredd 420
 ctfccqvngc rhcvtatvcgq tctnnpkvpg eccpvcecept iltvdpacg elsnctltkrk 480
 5 dcimgfkrdh ngcrtcqcin tqelcserkq gctlnpcpfg ltdaqnceic ecprprkkcr 540
 piicdkycpi gllknkhgdc icrckkcpel scskicplgf qgdshgclie kcreasasag 600
 ppilsgtclt vdghhkhnee shwdgcrecy cingremcal itcpvpacgn ptihipgqccp 660
 scaddfvvqk pelstpsich apgggyfveg etwnidscctq ctchsgrvlic etevcppllc 720
 10 qnpstqtqasc cpqctdqpfpr pslsrnnsvp nycnkdegdi flaaeswkpd vtcsicidids 780
 viscfesescp svscerpvlr kgqccpcyik dtipkkvvch fsgkayadee rwdldstchc 840
 yclqggtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiektn hrgevdleyp 900
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiic lsiiiaflfi 960
 ngkkqwipll cwyrtpkps slnnqlvsvd ckkgtvrqvd ssqrmlriae pdarfsgfys 1020
 15 mqkqnhlqad nfyqtv

<210> 35
 <211> 716
 <212> DNA
 20 <213> Human

<400> 35

gcagtaacctg gagtgtcctg cagggggaaa gcgaaccggg cctgaagtc cggggcagtc 60
 accgggggct cctgggcccgc tctgcccggc tggggctgag cagcgatcct gctttgtccc 120
 agaagctccag agggatcagc cccagaaac accctctctc ccgggacgce cgagctttct 180
 30 gaaggctgag gaaggcatga agagtgggct ccaactgctg gccgactgag aaaagaatt 240
 ccagaactcg gtctctatttt acagattgag aaactatggt tcaagaagta agaacggggc 300
 ttgagggaaat tccctgattc tctttatatg accctcaaat gaccatacta aacagtgtag 360
 35 aaggtctcttt taaggctcta aatgtccagg tctcccatcc cctgatgcct gacttgtaca 420
 gcagtggtgg agtagacggt ttctctcacc cagggttgac tcagggggat gatctgggtc 480
 ccattcttgt cttaagacc ccaacaaggg ttttttcagc tccaggatct ggagcctcta 540
 tctgggttagt cctgttaacct ctgtgtgctt ccggttaacc ggttaagtcac gtgagctcag 600
 35 ccccatcca cctaaccagg tggccacagg gattactgag gggttaagacc ttagaactcg 660
 gtctagcacc cgataagagc tcaataaatg ttgtctcttt ccaatcaaaa aaaaaa

<210> 36
 <211> 395
 40 <212> DNA
 <213> Human

<400> 36

ccaatacttc atttcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
 45 aaaaagctatg atttgatttc caacttttaa acattgcatg tctcttgcca ttcttaccat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaaat 180
 atgattatta cattggaatc cttagacctt ttgtgatatt ttcttaacttt gcactttcac 240
 50 gccagtagaa accaaagtca gggttaaccaa tgtctattta caaaagtgtt aaaccctaat 300
 tgcagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

<210> 37
 <211> 134
 55 <212> DNA
 <213> Human

<400> 37

ccctcgagcg gccgcccggg cagggtacttt taccaccgaa ttgttcaact gactttaaga 60
 60 aaccataaa gctgctctggc tttagcaac aggcctatca acaccatggt gactctccat 120
 aaggacacc gtgt

<210> 38
 65 <211> 644
 <212> DNA

<213> Human

<400> 38

5 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
 cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcctaagca acttcttcgc 120
 gggaaagatg ccagtgacgc cactgttaca attcaagatc ttgatctata tccatagatt 180
 ggaatatttg tggggccagca atcctcagac gectcactta ggacaaatga ggaacttag 240
 gcttgggtgaa gtttacgaac ttgtccaaaa acacacaact tgtaaaaggc acagccaaga 300
 10 ttccagagcca ggcgtctaaa attaaaaatga acaaatattacg gccacacagat aggagaaga 360
 aggatgttta tggttccagag gccagtcgct cacatcagtg gcagacagat gaagaaggcg 420
 ttccgaccgg aaaaatgtagc ttcccggtta agtaccttgg ccatgtagaa gttgatgaat 480
 caagaggaaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540
 tcaaaagcct ctttgaaaaa actggaaaaa aagcagttaa agcagtttct gtgggtctaa 600
 15 gcagatggac tcagaggttg tggatgaaaa actaaggacc tcatt

<210> 39

<211> 657

<212> DNA

<213> Human

<400> 39

ctttttgttt ggggttttcca atgtagatgt ctcagtgaaa tgtgcagata tactttgttc 60
 cttataggtt gcccaagtgt aattatggac aaatacatta aacaagggtt tctcggccca 120
 gctccctcct taactctctt gataactctg gaattctaagt ctgagggagc atttctgaat 180
 tagccagtggt tgtaccaact ttctgttagg aattgttatta gaataacctt tttttttcag 240
 acctgctcag tggagacatct tggggaaatga agtaggaaaa tagacatttg gtggaaaaaac 300
 agcaaaatga gaacattaaa aagactcatt caagtataata taaaaaggcg atggaattcc 360
 30 tggctccttt agcaaaaatga gaagaaaaaa ttctgctcag cagttattcac tgtgttaaga 420
 tttttttgtt tttcacagaa tggaaaaaat atgtgttaagt ggtatagatt ttaatcaggt 480
 aacagtcact ccagagatgt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
 taagaataat tactacattt aacattataa agtagagttc tggacataac tgaaaaattag 600
 atgtttgctt caatagaatt ttgttccacc ttgtattttc aacaaaaatt tcggaac

<210> 40

<211> 1328

<212> DNA

<213> Human

<400> 40

acaattttta aataactagc aattaatcac agcatatcag aaaaaagatc acagttaggt 60
 ctgggttagt ttttagagct cattatggtt agggctcgta agatgtatat aagaacctac 120
 45 ctatcatgtg gtatgtatca ctcattccat ttctcatgttc catgcatact cgggcatcat 180
 gctaataatgt atcctttttta gcactctcga ggaacacaaa gggccttttta tttttttaaa 240
 ggtaaaaaaat attccccaaa tattttgcac tgaatgtacc aaagggtgaag ggacattaca 300
 atatgacaaa cagcaactcc atcacttgag aagtagataa gaaaatagct tctaatacaa 360
 50 acttctcttca cagtgccgtg tctaccacta caaggactgt gcatctaagt aataattttt 420
 taagattcac tatatgtgat agtatgatat gcatttattt aaaatgcatc agactctctt 480
 ccacccatca aatactttat aggatggcat ttaatacaga tatttctgat tccccccat 540
 gcttttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagacaacac 600
 tgaagagatc agtagtaaga attccatttt cctctcatcg taaagacacc acaaatgtga 660
 actcaggaact atattttctaa gcctgcattt tctagtatgc ataattttct tagtaatttt 720
 55 atcagacagt ttttctatgg catctccaaa actgcattgc atcactatgc ttactttctg 780
 ttaatttttat gagaaggtag tcttcatatt aattgctttt ggacttactc cacactcttt 840
 tttattttct gactaatcag attttcoaat gagtgaagtt aaattggggg tcaataaagg 900
 attggattga catatggttt gccagcctat ggggtttacag gcaattggcca aacattttct 960
 60 tggagatcat atttataagc agccattgaa ttctcattat gggatgtgtg caactcttca 1020
 ttttatagag gtccattatga tagttttcat agggtgtttt taagaagttg ttgctctcct 1080
 gtgagtttaa ctatgttttac tactgggacc ctcaaaggga ataccaccta tgttacactc 1140
 ctgcactaaa ggcacgtact gcagtggtgaa gaaatttctt gaaaaagggt tatagaaatc 1200
 tggaaaaaag aaagagaagag ctctctgtat tgcataatgt gaagagaaaa aaagaaaaac 1260
 65 ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tattaatttt 1320
 tgaaaaaa

<210> 41
 <211> 987
 <212> DNA
 <213> Human

5

<400> 41

10

```

aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaaact 60
tgagctcttt tcaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatgggtg 120
taacccccgg cttatcagtc ggaatgggtg caccctctct gctgtggcat ggaagcagcc 180
atggagtggtg gggaggggcg aataagacac cctccacag agcttggcat catgggaagc 240
tggtttctacc tcttctctgg tcctttgttt aaaggccttg ctggggagcct tcctttttgg 300
tgctctttctc ttctccaacc aacagaaaag actgctcttc aaagggtggag ggtcttcctg 360
aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420
ggaggaggga ggaagctgta gggagatgct aaggtctcga aacaaggagg 480
gcagaatagg cagaggcctc tccgtcccgag gccattttt gacagatggc gggacggaaa 540
tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
cagccgggtg acctgggtca attttagcct ctaaaagcct cagttctctt atctgcaaaa 720
tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa ggggtatcaa 780
aatagtcttac ggccatacca cctgaacgtg gcctaacttc gtaagctaag cagggtcagg 840
cctggttagt acctggtatg ggaagatgat gaaaacatc ctgcccgagc ttggagttgg 900
actctgtctt aacagtagcg tggcacacag aaggcactca gtaataactt gttgaataaa 960
tgaagtagcg atttggtgtg aaaaaaa
```

<210> 42
 <211> 956
 <212> DNA
 <213> Human

<400> 42

```

cggacgggtg ggcggacgcy tgggtgcagg agcaggggcg ctgccgactg ccccaaccaa 60
ggaaaggatgc cctgagtcgc cctgcgcctc catccatctg tccggccaga gccggcatcc 120
ttgctgtctc aaagccttaa ctaagactcc cgccccggcg tggccctgtg cagaccttac 180
tcaggggatg tttacctggt gctcgggaag ggaggggaag gggccgggga gggggcaccg 240
cagggcgtgtg gcagccacac gcaggcggcc agggcgggca gggacccaaa gcagatgac 300
cagccacctc cagcccaactg cctccccga atgcatttgg aacccaaagc taactgagc 360
tcgcagccccc cgcgcctctc ctccgcctcc catcccgctt agcgctctg agcagtgagc 420
gcaggccctg tccagccccc agtgcgctcg ttcgggtccc cacagactgc cccagccaac 480
gagattgtctg gaaaccaagt caggccagggt gggcgggaca aagggccagg tgcggcctgg 540
ggggaacagg taacctcgag actggactgt tttttcaca catcgctgcc gcagcgttgg 600
gaaggaaaag cagatgtaaa tgatgtgttg gtttacagg tatattttt ataccttcaa 660
tgaatttaatt cagatgtttt acgcaaggaa ggacttacc agtattactg ctgctgtgct 720
tttgatctct gottaccgtt caagaggcgt gtgcaggccg acagtccgtg accccatcac 780
tcgcagacc aagggggcg ggaactgctg ctacgcccc cgtgtgtctc cctcgcctc 840
ccttctcttg gcagaatgaa ttgatgcgt attctgtg cgcctatctg gcagggtggt 900
ggtattctgt catttacaca cgtcgtctca attaaaaagc gaatttact ccaaaa
```

<210> 43
 <211> 536
 <212> DNA
 <213> Human

<400> 43

```

aaataaacac ttccataaca tttgttttcc gaagtctatt aatgcaatcc cacttttttc 60
ccctagattt ctcaatgtta aagagagggt aaaaaaggct caggatagtt ttacactcac 120
agtggttagt gctttttatt ttactcttgg aaatagagac tccattatgg ttttgacatt 180
ttgggaaccc agtttttacc ttgtgtcagt aaaaacataa gatagtttga gacatataga 240
tctaaataaa gacatttgaa ggggttagttt gaattctaaa agtagttaat agccaaatag 300
cattctctac ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaaa 360
attttttcca gatgaaatt gtgccacttc caattgacta atgaataata aggagcaga 420
ctggaaaaaa tggggttatgc cacccttaaa accctttctg gtaataatta ttttagctaa 480
agggtggttt ccccgagcac tggacctgga caggtaggggt tccgtgggta accagt
```


<210> 44
 <211> 1630
 <212> DNA
 <213> Human

<400> 44

ggggagggac gactatggaa cctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
 gctccctggg caccagtc caggcaggag cagctgtttt ccaccccttc ccagacaagc 120
 tctattttta tcacaaatgac cttagagag gctccccagg ccagctccaag gtgtcccatc 180
 atccccctctg gagggaaag gcaggaaaaat tctccccggg tccctgtcat gctactttct 240
 ccatccccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
 gtgatttccc ttaggccagc gaactgggccc tccagctcat ctgttctctc tgggcccattc 360
 catggcagggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
 gactttacct gattgccctc agtttgggtg tgcttatctg gaaagagaga gacaagagat 480
 tactttgtac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
 gacaggattg gctcagatga cccctgaggg ctctccagc cttgaaatgc attccatgat 600
 attaggaaat cggggggtgg tgggtgtggt gggctagtgt ggtttgaatt tagggggccga 660
 tgaagcttggg tacgtgagca ggggtgttaag ttagggtctg cctgtatttc tgggtccctc 720
 ggaattgtcc cctctctcag gtgcagacct cagtcacagt gtccataatg cttgggtggc 780
 agtagacatt atcctgcccc atcccttccc cagtgacatc tgacctagct agtgccctgt 840
 gccagtgac ctgggggagc ctggctgcag gccctcactg gttccctaaa ccttggtggc 900
 tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct tagttttcca 960
 gagtgtgctg gtatagcctt cttagagttc agaattattg ctccaggatc agctgggggt 1020
 atgagatttg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
 ttggggagac ttgtgttttg ggaacttacc ggtgtgatgt agatctggaa cccccagggt 1140
 aggtctggag gatttaaggt cagtatggaa gatagggttg ggaacagggtg ctttgggaatg 1200
 aaagagtgac ctgttagagg tccctgggccc tcaggaaatgc tctcgtctgt ctgaagatga 1260
 gaaggtgtct tttactcagtt aatgatgagt gactatattt accaaaagccc ctacctgtct 1320
 ctgggtccct ttatgcacag gagactgggg ctccagggccc agggacacaa 1380
 tcaggccctct ggcctgaggca tagcataga ggaatccatt ctacctgcat tccccaggag 1440
 actgacagga ggcagccttg agaaaccggc agttcccaag ccagcgctctg ctgtgtctct 1500
 cattgtcact gccctctccc caacctctcc tctaacccac tagagattgc ctgtgtctct 1560
 cctctgtcct ctgtagaagt gcagctctgg cccctcaata atgtcttctg cattcatctg 1620
 caaaaaaaaa

<210> 45
 <211> 169
 <212> DNA
 <213> Human

<400> 45

tcttttgcct ttactttttt ttttttctat taacaggagt cttattacac atagggtctga 60
 taaaactcgt ttatgatctt cagctctgatt ccagtgctgc ataactagat aaggtatgaa 120
 ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaaga cttagtgtga

<210> 46
 <211> 769
 <212> DNA
 <213> Human

<400> 46

tgcaggctat atttactatc ggcaataaaa ggaagcaaag cagtattaa cagcggtgga 60
 atttgtcgtc ttcacttttt ataaagtgtc acataaaaatg tcatatttcc aaatttaaaa 120
 acataaactcc agttcttacc atagaaacag catgtgtgatc acgaaggatc tctttgaaa 180
 aaaaacaaaa aaaaacaaaa aacaatgac tcttctgggt atcacatcaa atgagataca 240
 aagggttact aggcaatctt agagatctgg caacttattt tatataaag gcactctgta 300
 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataatgtat taaatgcaag 360
 ctctatataa tgacacaaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
 gggcagctcc tttctgtata gttctgattc tctctcatat ataggcagct cctgatcatc 480
 catgcccagt aatgagaaaa caagcatgga atatataaac ttttaacata aaaaatggtt 540
 tatttttgaa taaaaacaaa tttccattg aaaccttcaa aaactttgca gtagaggtt 600
 ttgatatatg tgtacaagta gtacctctt agtgcaagaa aacatcatta tttctgtctg 660
 cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtgtgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47
<211> 2529
<212> DNA
<213> Human

<400> 47

10 tttagtctat agtaaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaca 60
gtgaaaattat gtgactgggt aaggtgtgcc actgtacata tcatctttt ctgactgggg 120
tcaggacctg gtccctagtcc acaagggttg caggaggagg gtggaggcta agaacacaga 180
aaacacacaa aagaaaaggaa agctgccttg gcagaaggat gaggttggtg gcttgcgcag 240
ggatggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
15 gccttactta gctcctggca gagggtgagt ggggacctac gaggttcaaa atcaaatggc 360
atttgccag cctggcttta ctaacaggtt ccacagtgcc ctctgttggc tgagctctcc 420
tgggtcact ccatttcatt gaagagtcca aatgattcat tttccacc accaactttc 480
attattcttc tggaaaccca tttctgttga gtccatttga cttaagtct ctctccctcc 540
actagtgtgg gccactggc tgaggggggt ccaccaatt cctctagag aagacacact 600
ccagagggccc ctgcaacttt gcggattttc agaaggtgat aaaaagagca ctcttgagtg 660
20 ggtgccagg aatgttttaa atctatcagg cacactataa agctggtggt tcttctctac 720
caagtggatt cgcatatga accacctact caatacttta tattttgtct gtttaaacac 780
tgaactcttg tgttgacag tacaaggag aagagatggg gactgtgaag aggggagggc 840
tccctctatc ttcctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
25 gcaatagatg gggcttccca ccatttgttg gttattgctg ggttagacca ggagcagtg 960
ggatggcaga gttagagaga gggccagagg aaagccatc tccctccagc tttgggtct 1020
ccagaaaagg gctggatttc tgggatgaag cttagaaggc agagaccaga ctgttccacc 1080
aggtgaagag tctaccctgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140
30 tttatgaact gaaaatcaaa tcaaggtatt ggaagaataa atttccctac aggtccacag 1200
gagggagaagc cacacatatc cattgtgctg gggctcccca accgctgtcc acctgcttt 1260
acaaatcact aggggtgtgc tgcctggcag tccatgctt cctgggtttt accagcata 1320
caaggagttt tccaggaaat ctatcaagcc ataccaaaat cagggtcaca tgggggttt 1380
35 ccctttctct gcctcttcat aaaaagacaac ttgcttcttg aggttctgtg tttttgat 1440
gcagtgtggc tgactagaca aagcccccag tttctgttgg caggttctgg gagaggatgc 1500
attcaagctt ctgcagctca ggggacaggg ctgctgttgc agtattact gctcggagc 1560
tccaaatccc accaaaagtc ttgactccagg tcttctctaa tgcacagtag tcagtctcag 1620
cttcggcagc attctcggtc gbatgttctc tggcagagag aggcacagat acatagtttt 1680
agggagaaaag ctatgtggaa acctgtgagt tctcttgagg ccaaagacac tgagcacagc 1800
40 tgcacggaaa ccaggaagtc attcaagttg tctcttgagg cgaagtgaac ccagcttag 1860
ccagagccaa taaaagatct ttgagctctc atgtggcacg atttcttgc ctctctacag aggaagaaga 1920
ctactgcatt tatgattttt atgggcacag gacggcgact ggttttgaa agggggaact 1980
gggggagttg gaaggggaag ctggtctcag aagcaactta ccaaggggta tttaaagaca 2040
45 tgaaaatttc cagaaatacc tttctgttgc tcccttgtt cctcttgaga ttaactcagg 2100
tgaatttata ctgcagactt tctctcttt ctgcctcttc cctctcgaga gtcaggacct 2160
cgagaactgt ctgaaacaag attctatggt tgcacctag agagatgaat caatggcaag 2220
gcctgaagtt atagatgttt tacagcgggt gcgatattca ggggtcctag ccaactggct 2280
tgcagttcca aagctctgat gaagaaacaa gactcctga tgtgttactg tcccactga 2340
50 tttccagggt caagattagc cagggaagcca aacaccagga gtgtgggttg cagctacca 2400
gtccagagcc ctgccacgga tgtacgcagg agcccagat gtagcaatca ggagccagaa 2460
catgatccac agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacataact 2520
gggggtgccc

<210> 48
<211> 1553
<212> DNA
<213> Human

<400> 48

60 tttttttttt tttttgtttt ctggggacaat taaagctttat tttcatata tatatatatt 60
ttcatatata tatatacata catatataaa ggaacaattt tgcataatta cacacctgac 120
aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgagact 180
ctagccagcg ccggttttcca tccctaagta ccatctctct atttgggccc ttttagggt 240
65 gggggccctga gcttggtttg tagaagtttg gtgctaataa accatactgt ttaatcccca 300
tgaaggacag gttagacctc atctttgtct gctccccgct gcctttcagt tttactgat 360

ccatcaagag ggctatggga gccaaagttaa caccgggggat tgagggctaatt tcacctgaac- 420
 tcgaaaacag gccccagctt cctcacgcga ggcacgcgtc ttttctcttt ttttctcga- 480
 gacggagctt cgcgtgtgtt cccaggcttg agtgacgttg caccggtctcg gctcactgca 540
 agctccacct cctggatcca taccattctc ctgcttcagc ctcccgagta gctgggacta 600
 taggtgcgcaa ccactacgccc ttttttgtat ttttttgtat ttttttgtat gactagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgtcctg acttttgtat ccgcccgcct cggcctccca 720
 aagtgtcggg attacaggcg tgagccacca cacttggccc cgcacgtat cttttaagga 780
 atgacaccag ttctgtgctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggg 840
 agacaggagg gtgtgtggcag caacactgca gctgtctctg gatgtctctg ggtgtctctc 900
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctcgg gtgtgtctct 960
 acttcagtgg tgcacctgga tgggtgaagc cagcctttgg ggcaggaaac cagctcagag 1020
 aggtaccoca gctcagctgc tggcaggagc caggatttta cagccataat gtgtgtaaa 1080
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140
 ggatgagctt cactcaacgt ggagatgggt gtggaactgt ccttgaaggc cgggctcttg 1200
 agggccaagt gaggctctca ggtcctaacc ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cggggggagc aggaggtctt tctctagtcc ctttggaggc tttgtctcgg agaagagta 1320
 gcaggagctt gggaatggtc caggcaggga agggagctga agtgattcgg agtaaatgcc 1380
 tcagatcgat gttattctct ccttggtctc ccggagccct cttgtaccgg ctgctgcct 1440
 gcaggagggc catctctctt gggagcttat ctgacttaac ttcaactaca agttcgtct 1500
 tacgagaccg ggggtagcgt gatctctcgc ttcctgagc gctgcacgg cag

<210> 49
 <211> 921
 <212> DNA
 <213> Human

<400> 49

ctgtgtgtccc agctactcag gaggctgagg cgggaggatt gcttgagccc agggagttaga 60
 tgtgtcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataacct 120
 gcttcagaaa acaaaacaaa aaaagcagaa acgtggaagg ggtcgtgtta cgggaaaacc 180
 gctgtgcaga acacttggct actcctaccc cagatcagtg gacctgggaa tgagggttgg 240
 tcccgaggag cttttctcca agctgttgcc accagaccgg ccatgggaaac cctggccaca 300
 gaagcctccc ggggagtgag ccagagcctg gacgcgtgtg ctgatgtgtc tggggtggag 360
 ggaggtgtgg gagtgtgcaa ggtgtgtgt gtgcccgggg ggtgttcatt ggcaagcatt 420
 tgcgtgcctg tgtgtgtgctg tgcccctccc ctgcagccgt cgggtgtatc tccctccagc 480
 cctctgcoca cctctgagc attgtctgtc cactgagac tgcccagaga cagcagagct 540
 ccacgtggtt ttaaggggag accttccctt ggaacctggg gctcgcgggt atctcatgac 600
 caggtgtctaa atgacccgac atgcatcacc tgcttttcca tgaccaacct cctgtccccc 660
 gctcccgctg cctgcccggc tggcgtctca gctgtgatgc tgctcctgac attgtgttcc 720
 actgtagcaa actacattctt ggatgggaat ttctatgtac atgtgtggca ttgtggaaa 780
 ttcataataa atggaattga tttagaaga caaaaagctg tgtgtctctt ccagcacgga 840
 taactttgacc tcttgcctac aaccccttcc ttgggtccga ggtcgttagc tttgttccact 900
 tcagatggtt gggggcgggt g

<210> 50
 <211> 338
 <212> DNA
 <213> Human

<400> 50

atgatctatc tagatgcoct accgtaaaat caaaacacaa aacctactg actcattccc 60
 tcccttccag atattaccoc atttctctac agccaaactt tccaaaactt 120
 cctgttctgt ctttacttcc tcatgttcaa cccaccctgt cttagctacc accctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgata cataactaat gatcctcgt 240
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgcata 300
 gtaagaaact ttttttctgt aattcttgtt tctcttgg

<210> 51
 <211> 1191
 <212> DNA
 <213> Human

<400> 51

	ctagcaagca	ggtaaacgag	ctttgtacaa	acacacacag	accaacacat	ccggggatgg	60
	ctgtgtgttt	ctagagcaga	ggctgattaa	acactcagtg	tgttggctct	ctgtgccact	120
	ctgtgaaaaa	aatgaatttg	gtaaggaaac	gttaataaga	aaatgtgcct	tgctaacctg	180
	gcacattaca	acaaagagct	ggcagctcct	gaaggaaaag	ggctgtgtcc	gctgcgcgtc	240
5	aaacttgtca	gtcaacctcat	gccagcagcc	tcagcgtctg	ccctccccagc	acacctcat	300
	tacattgtctc	tgtctggcct	gatctgtgca	tctgtctcga	gacgtctctg	acaagtctgg	360
	aattctctcta	tttctccaact	gggtcacaag	cgggattttc	ccctgctctc	cttctgtcac	420
	ccccgctcct	ctccccagag	aggctccttg	atttatggta	gctttggact	tgcttccccg	480
	tctgactgtc	cttgacttct	agaatggaag	aagctgagct	gggtgaaggga	agactccagg	540
10	ccatcacaga	taaaaagaaa	atacagggaag	aaatctcaca	gaagcgtctg	aaaaatagag	600
	agaacacaa	aacgaccagc	catttgaaag	aaaaggcctt	ggggagagaa	tggtctctag	660
	atggaatcag	cagcgaaaaa	gaacagggaag	agatgaagaa	gcaaaatcaa	caagaccagc	720
	accagatcca	gggtctagaa	caaagtatcc	tcaggcttga	gaaagagatc	caagatcttg	780
	aaaaagctga	actgcaaatc	tcaacgaagg	aagaggccat	tttaaagaaa	ctaaagtcaa	840
	ttgagcggac	aacagaaagc	attataagat	ctgtgaaagt	ggaaagagaa	gaaagagcag	900
	aagagctcaat	tgaggacatc	tatgctaata	tccctgacct	tccaaagtcc	tacataacct	960
	ctaggtttaag	gaaggagata	aatgaagaaa	aagaagatga	tgaacaaaat	agaaaagctt	1020
	tatatgccat	gaaattataa	gttgaaaaag	acttgaagac	tggagaaagt	acagttctgt	1080
	cttccaattc	gttgcgccat	cagatgactt	taaaaggtac	aggagataaa	gtttaagatg	1140
	atgggcaaaa	gtccagtgtg	ttcagtaaa	tgctaatac	aagttggagg	t	
	<210>	52					
	<211>	1200					
	<212>	DNA					
	<213>	Human					
	<400>	52					
	aagcgggact	ctcactctat	caaccccagg	ctggagtcgg	gtgcgcccac	cttggctccc	60
	tgcaacctcc	ggctccagag	ctcaagcaac	tctctgcct	cagtcgctct	agttagctgg	120
	actacaggca	caacaccacca	tgcccagcca	atttttgcat	ttttgttaga	gacaggggtt	180
	cgctctctgt	ccaggccggc	atcatatact	ttaaatcatg	ccagactgac	tttaatactc	240
	aatacaatat	atcaggttgg	tttaaaaaata	attgtctttt	tattattttg	cttttttttg	300
	accacacctta	atgctatgta	aatagtgttg	atactgttgc	tttaacaacag	tatgacaatt	360
	ttggcttttt	ttttgtatta	ttttgtattt	ttttttttta	tgtgtgtggt	tttttttttt	420
	ttctcagttg	tttcaattcc	tccttggttg	aatccatgga	tgcaaaaacc	acagatatga	480
	agggtctggc	atatatgcat	tgatgtattg	cctattatat	tagttataaa	gtgtcattta	540
	atatgttagt	aaagtatttg	tacagtggaa	agagttagtg	aaaacataaa	catttggacc	600
	tttcaagaaa	ggtagctttg	tgaagttttt	caccttcaaa	ctatgtccca	gtcagggctc	660
	tgctactaat	tagctataat	cittgcacaa	attacatcac	cittgagctc	cagttgcttc	720
	acctgtaaaa	tgaagaagact	ggatactctc	taaggtcact	tcacgacctg	tcatttctata	780
	actctgttat	gctgaggaag	aaattcacat	tgtgttaact	gtatgagtca	acttgaataa	840
	gattattaaa	gtgggaaaaa	gccaatgtct	tctcttagaa	agctcaacta	aaatttgaga	900
	gaataactct	ttcaattttt	taagaattta	aatattttta	agggtttgac	ctatttattt	960
	agagatgggg	tctcactctt	tcacccagac	tggagtacag	tggcacaact	atagctcact	1020
	gctgcctcaa	atccatgggc	tcaagtgtac	ctctgcagca	gtgcgcagca	gtagcggcga	1080
	ctatgggcat	gtgccaccac	gctctggtaa	catttgtatt	gacctattta	tttattgtga	1140
	tttatatctt	tttttttttt	tctttttttt	ttttttcaaa	aatcagaaat	acttattttg	1200
	<210>	53					
	<211>	989					
	<212>	DNA					
	<213>	Human					
	<400>	53					
	aagcoaccac	tcaaaaattc	ctatacattt	tcacagcaga	gacaagtga	catttatttt	60
	tatgctcttc	ttcctatgtg	tatttcaagt	ctttttcaaa	acaaggcccc	aggactctcc	120
	gattccaabta	gtccttgggc	tggtcagact	tgaggagctc	caggagactc	ctacaagtgc	180
	agagtgactc	tttaccaca	taaacctgat	atacatgcaa	aaagcagac	cctctctcca	240
	ggaattgtgcc	atttcagagt	cacagcacc	atgcagaaaa	gttggaattt	tccttggaa	300
	gcactgtgat	agaggtgctt	acatgaacct	tgctactgtc	cttctttttt	tttgaagac	360
	gtttctgttg	tgcccagctt	gagtgcaatt	cgtgactgta	ctcaactgaa	ttccacctcc	420
	agggtcgaag	attctctctg	tcagcctctc	agtagctggg	ttacagggac	tgccacactg	480
	ccggctcaatt	ttgtattttt	gtagagatgg	atttctccat	ttggctcagg	ggctctgaac	540
	cccaacctca	gtgactgtgc	acctcagcct	cctaagtgtt	ggattacagg	atgagccacc	600

cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaag aggaaataat 660
 ttctctgaag tacttgataa aatttccaaa caaaacacat gtccacttca ctgataaaaa 720
 atttaccgca gtttggccacc taagagtatg acaacagcaa taaaagttaa ttccaagag 780
 ttaagatttc ttcagcaaaa tagatgattc acatcttcaa gtcccttttg aaatcagtta 840
 ttaattattt tctttctcca ttccactctg aatgactgca gcaatagttt tttttttttt 900
 tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtgc actggcgcaa 960
 gccgcgtcca ccgcaatctc tgccaccgcg

<210> 54
 <211> 250
 <212> DNA
 <213> Human

<400> 54

catttcccca ttggtctctga ttgtgaagat ttagttaaag aggctgtaag tcaggttcga 60
 gcagagcgca ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120
 agtggctggg tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180
 aaaggccatt ctttaggaac tgcatctggt aaccacacc ttgatccaa agctagggaa 240
 acctcagttg

<210> 55
 <211> 2270
 <212> DNA
 <213> Human

<400> 55

gggcccccca ggaagcgccc cgcctctccc gcttctctcg cggggacctc gagcgaaaaga 60
 ggccccgcgc cgcgccagcc ctgcgctccc tgcccaccgg gcacacccgc ccgccacccc 120
 gacccccgctg cgcagctcgt gtccgctgca caccagcttg ttggcgcttt cgtcgccgcg 180
 ctgcgccggg gctactccgt cgcgccacaa tgagctccc cctgcgccag gcgtctcgct 240
 tagtctgcac ccttctccac ttgaccaggc ttggcgtctc cacttgcccc gctgctctgc 300
 actgccccct gaggagcgcc aagtgcgcgc cgggagtctg ctgtgtccgg gaagctctgc 360
 gctgctgttaa ggtctgcgcc aagcagctca acgaggactg cagcaaaaac cagccctgctg 420
 accacaccaa ggggctggaa tgcaactctg gcgccaaagt caccgctctg aaggggtatct 480
 gcagagctca gtcagagggc agacccctgt aatataactc cagaatctac caaaacgggg 540
 aaagtctcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600
 ttctctctgt tccccaagaa ctatctctcc ccaacttggt ctgtcccaac cctcggtctg 660
 tcaaaagtac cgggcagctg tgcgaggagt gggctctgtga caggaatagt atcaaggacc 720
 ccatggagga ccaggacggc ctcccttgga aggagctggt attcgatgcc tcagaggttg 780
 agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggtcc 840
 ctgttttggt aatggagcct cgcactctat acaacccttt acaaggccag aaatgtattg 900
 ttcaaacacac ttcatgtgtc cagtgctcaa agacctgtgg aactggatc tccacacgag 960
 ttaccaatga caacctgag tgcgcgcttg tgaaaagaaa cggattttgt gagggtgggc 1020
 ctctgtggaca gccagtgtac agcagcctga aaaagggcaa aagatcgac aagacaaaga 1080
 aatcccccca accagtccag ttactctacg ctggatggtt gagtgtgaag aaataccggc 1140
 ccaagtactg cgttctctgc gtggacggcc gatgtgcac gccccagctg accaggactg 1200
 tgaagatgct gttccgctgc gaagatgggg agacatttct caagaacgtc atgatgatcc 1260
 50 gttgctgcaa atgcactac aactgcgccg atgccaatga cagcagcttt cctctctaca 1320
 ggctgttcca tgacattcac aaatttaggg actaaatgct accbtgggtt ccaggggaca 1380
 ccttagcaaaa caaggagaaa gagtgtcaga atcagaatca tgggaaaaat gggcggggtg 1440
 ggtgtgggtg attggaactca ttgtagaag gaagccttgc tcatcttctg ggagcattaa 1500
 55 gttattctga aactgccta ggtgctggtg cggatggaca ctaatcgagc cagctatgga 1560
 gaatatctgt cttcatagta ttggagcaca tgttactgct tattttctga gctgtgtgag 1620
 ttgatgactt tctgttttct gtttgtaaat tatttgcata gcatttttt tctaggcttt 1680
 tttccttttg ggtttctaca tgcgtaaaag agataataag attagtttga cagtttaaa 1740
 ctttttatgt tcttttgaca aaagttaagt ggagggcatt ccatccctc ctgaaaggaa 1800
 60 acactccatg agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860
 ggtgttttaa gactgaattg tttatttatc aaaatgtagc taaactgaga ggaggggaaa 1920
 tghtaactag gaataattg taaatgattt taattttata ttcagtgaag agattttat 1980
 tatggaatta accattttaa aaagaaatat ttaacctata tctgagtgtg tgccattcgg 2040
 tttttttaga gttgttccaa agtcaatagg aacaacctag ctacagctact caactattca 2100
 65 aacaggactt attgggatac agcagtgaaat taagctatta aaataagata atgattgctt 2160
 ttataccttc agtagagaaa agtctttgca tataaaagta tttttaaaaa acatgtattg 2220
 aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

5 <210> 56
 <211> 1636
 <212> DNA
 <213> Human

<400> 56

10 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcctaaagc agggaaaggga 60
 agcgctcgag ttggaaaagg accgctgctg ctggccgaac tcaagcccg ggcgcccac 120
 cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctcccc agatggctcc 180
 tggtttgctt ggtctcaagg acactgcact gtcaaatga tcccttgccc gtggaggag 240
 cagttcatcc ctaaagggtt tgaagccaaa agcgaagta gcaaaaatga gacgaaagg 300
 15 cggggcagcc caaaagagaa gacgctggac ttgtgtcaga ttgtctgggg gctggccttc 360
 agcccgctggc ctccccacc cagcagggaag ctctgggcac gccaccacc ccaagtgcc 420
 gatgtctctt gctgtgtctt tgctacggga ctcaacgatg ggcagatcaa gatctgggg 480
 gtgcagacag ggtcctgtct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
 agcttcacac ccagtgggcag tttgattttt gctcgcgctg caggggataa gactcttcgc 600
 atctgggaac tgaataaaca cggtaaacag attcaagtgt tatcgggccca cctgcagtgg 660
 20 gtttactgct gttccattct cccagactgc agcatgctgt gctctgcagc tggagagaag 720
 tcggctcttct tatggagcat gaggctctac acgttaattc ggaagctaga gggccatcaa 780
 agcagtggtt tctctgttga ctctctcccc gactctgccc tgcctgtcac ggctctctac 840
 gataccaatg tgattatgtg ggacccttac accggcgaaa ggctgaggtc actccaccac 900
 acccaggttg accccgccat ggaatgacag gacgtccaca ttagtctcact gagatctgtg 960
 25 tgcctctctc cagaaggctt gtacctgccc accgtggcag atgcagact ccttcaggatc 1020
 tggggccctg aactgaaaaa tcccattgca ttgtctccta tgaccaatgg cctttgctgc 1080
 acatttttct cacatgggtg agtcatgtgc acagggacaa gagatggcca cgtccagttc 1140
 tggacagctc cttaggttct gtctcactg aagcacttat gccggaaaag ccttcgaagt 1200
 30 ttcttaacaa ctttaacca gctagcactg ccaatcccca agaaaaatga agagtctctc 1260
 acatacagaa ctttttaaag aacaccacat ctgtgtcttc ttgttagcag tgaaatcgt 1320
 cctgtcaaa gagggtgtgt gaataatggg ccaaacatct ggtcttgcat tgaatatgca 1380
 attttttggg attgtgaata gaatgtagca aaaccagatt cacgtgtaca taaccagatt 1440
 tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acctatattg 1500
 aagacaattt gatcataaat aaaaaattat gacaattgtc tgggaaaaaa aaaaattgag 1560
 35 aagatgggtg aggggtggat ggaatgaggag cgtgtgtgac ggggctgca gcggttggg 1620
 gacctgtgc tgcgtt

40 <210> 57
 <211> 460
 <212> DNA
 <213> Human

<400> 57

45 ccatgtgtgt atgagagaga gagagattgg gaggggaggg gagctcacta gcgcataatgt 60
 ccctccaggg ggcctgcagat gtgtctgagg gtgagcctgg tgaagagaaa gacaaaagaa 120
 tggaaatgagc taagcagacc gcctgggggtg ggagggccag cccattttgta tgcagcaggg 180
 ggacaggagcc cagcagaagg cctccattcc ccaggactct gaggactcgt gagaccatcc 240
 50 atgcccgcag agccctctct ccaactccat cctgtccagc cctaattgtg caggtgggga 300
 aactgagcgt ggggaagtac atagcaagtg actggcagag ctgggaactgg aaccaacca 360
 gcctctcaga ccaaggttct tccatcaat ggaatgctag agactccagc caggtgggta 420
 ccgagctcga attcgtaatc atggctcatg ctgtttctctg

55 <210> 58
 <211> 1049
 <212> DNA
 <213> Human

<400> 58

60 atctgatcaa gaatacctgc cctggctact ctgcgagatg ttctgtccac ttgttcacat 60
 tgaggaccaa gatattcttt tttacagagg cactgtgttc gtctaacaca gacacctcca 120
 tgacgaacat ctggctgagt tttgcagtt ctgcagaagt cccctcccca gctcggacta 180
 cagcagcaat ttcccgctgg ggtgcagtag ccgtttcgac agagcctgga gcaactctga 240
 65 gtcagtgctt gtgcaggttg taacctggct ctgcattctc ctgggaactaa aggtcttttg 300
 ggaatctaaa tttttagag ttttccattg tgagtctggg tcatactttt actgcttgat 360

```

aaaaatgtaaa cttcacctag ttcattctct ccaaatccca agatgtgacc ggaaaagtag 420
cctctacagg accactagt gccgacacag agtgggtttt cttgocactg ctttgtcaca 480
ggacttttgt ggagagttag gaaattccca ttacgatctc caaacacgta gottccatac 540
aatcttttgt actggcagcc ccggtatata aatccaccaa ccaaggacc attactgaat 600
ggcttgaatt ctaaaagtga tggctcactt tcataatctt tccctttat tatctgtaga 720
attctggctg atgatctgtt ttttccattg gagtctgaac acagtatctg taaattgatg 720
tttatatcag tgggagtgtc atccacagca catctgcttg gatcgtggag cccatgagca 780
aacacttcgg ggggtctgtt ggtgctgttg aagtgtgggt tgctccttgg tatggataaa 840
ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagctctg gaaatcactt 900
aaccatccca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
aaaaaccgtg cagggccaaa gagcagttgc cctcccgat gctttctgtg gagttctgca 1020
acttcaagaa agactctggc tgttctcaa

```

```

<210> 59
<211> 747
<212> DNA
<213> Human

```

```

<400> 59

```

```

tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
ccttaattta caaagcctca gtcatctata cacattaggg gatccacagt gttcaaggaa 120
cttaaatata atgtatcata ccaaccacag taacccaagt acaaaaaata ttcatataaa 180
gttgttcaca cgtaggctct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
ctcgtctgtc ccaacacaaat gtttaagaag tcaactgcaat gtactccccc gctctgatga 360
aaagaagccc ctggcacaata agattccagt gccctgaag aggcctccct cctctgtggt 420
gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
ccctcgggca ggcaacggca gtggactcat ctggtgatg gctgtagatg ctaacactgg 540
ccaattcaat gccacacct ctgggttacc tttgagggca tttctcaga cagaagcccc 600
ttgaagccta gtagggcag gatcagagat acaccggtgt ttgtctcgaa gggctccaca 660
gccagtagc acatgcttgc agaagtagta tctctggact tctgctccca gtcgaccggc 720
cgcaattta gtagtaatat cgcccgcc

```